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Abstract
The E2F family of transcription factors are key regulators of the mammalian cell 
cycle, integrating gene expression with cell cycle progression. Physiological E2F 
arises when a member of the E2F family complexes with a member of the DP 
family. The E2F/DP complex can be directly and indirectly regulated by a variety 
of proteins involved in cell cycle control including members of the RB family of 
tumour suppressers, members of the HAT (Histone Acetyl Transferase) family 
and the p53 tumoin suppresser.
Previous work in the laboratory has now shown that the 14-3-3 family of 
molecules can influence the activity of E2F. This is dependent on the ability of 
14-3-3 to bind to the DP3 partner. Using a DP3 mutant that was unable to bind to 
14-3-3 but that retained its nuclear localisation, this study has further elucidated 
the role of 14-3-3 in influencing the activity of E2F. 14-3-3 can positively 
influence E2F-mediated cell cycle progression as well as negatively regulate the 
apoptotic ability of E2F. Specifically, 14-3-3 allows efficient S-phase entry as 
well as control over E2F-mediated apoptosis. This study suggests that this could 
be through the regulation of E2F/DP protein levels. The activity of 14-3-3 is 
dependent on its ability to bind DP3 since a mutant DP3, unable to bind 14-3-3, 
displays delayed S-phase entry and an enhanced ability to induce apoptosis. 
Interestingly, the interaction between DP3 and 14-3-3 was shown to be responsive 
to DNA damage, indicating that the interaction between these two proteins may 
be important in initiating a checkpoint control mechanism.
The results presented here point to a new role for 14-3-3 in the regulation of both 
the cell cycle and apoptosis. This regulation is carried out tlirough the influence of 
14-3-3 over E2F, mediated by the DP3 component.
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Chapter 1 : Introduction
1.1: The Biology of Cancer 
1.1.1: Introduction
Cancer cells are defined by two heritable properties: they and their progeny (1) 
reproduce in defiance of the nonnal restraints and (2) invade and colonise 
territories that are normally reseiwed for other cells. An isolated abnomial cell that 
does not proliferate more than its neighbours does no significant damage, no matter 
what other disagreeable properties it may have. If however, its proliferation is out 
of control, it will give rise to a tumour, or neoplasm, a relentlessly growing mass of 
abnormal cells (Alberts et al., 1994).
It is the genetic and epigenetic changes within a small set of genes within tumour 
cells that are responsible for neoplastic development. In this way, oncogenes and 
tumour suppresser genes play key roles in the development o f cancer. Oncogenes 
are genes that are upregulated in tumour cells and whose protein products are 
required for cell cycle progression whilst tumour suppressor genes are genes that 
are disabled and whose protein products play a key role in halting cell cycle 
progression (Alberts et al., 1994).
Normal cell cycle development can be divided into different sections. Gapl (Gl), 
Synthesis-phase (S-phase), Gap2 (G2) and Mitosis (M) ai'e the traditional 
subdivisions of the cell cycle. G l, S-phase and G2 constitute the interphase portion 
of the cell cycle whilst mitosis involves separation of the duplicated DNA and 
finally, cytokinesis, or cell division (Figure 1.1 A).
When the cell undergoes mitogenic stimulation to divide it will upregulate a set of 
genes involved in the progression through G l. In late Gl the cell reaches the 
restriction point, after which it is committed to entering S-phase where its DNA 
will be replicated. Cells in Gl that have not committed to enter S-phase enter a 
resting state called GO where they remain until they decide to re-enter the cell 
cycle. Once past the restriction point the cell is no longer under the control of 
external signals and must divide unless cellular insults occur.
The G2 phase is a gap where the cell ensmes that DNA replication is complete 
before mitosis, and finally cell division, is undertaken. If cellular insults such as 
DNA damage occur the cell initiates a checkpoint control mechanism whereby cell 
cycle arrest is initiated at either the Gl/S or G2/M boundaries. The cell then either 
repairs the damaged DNA or commits to programmed cell death, or apoptosis. It is 
the mis-regulation of the genes involved in this intricate ‘stop-go’ mechanism of 
cell division that ultimately leads to the development of cancer.
1.1,2 The cdks and cdkis in Cancer
The mitogenic dependent progi'ession tlmough the Gl portion of the cell cycle and 
the entry into S-phase are regulated by the several types of cyclin dependent 
kinases (cdks) and their inhibitors, the cdkis. The cdks provide the catalytic portion 
of the cyclin/cdk complexes that are responsible for cell cycle progression whilst 
the cyclin portion of the complex provides the regulatory role, thereby activating 
the cdk.
The cyelin D- and E-dependent kinases control the progression through the Gl 
portion of the cell cycle. Following mitogenic stimulation the D-type cyclins (Dl, 
D2 and D3) (Matsushime et a l, 1991; Xiong et al., 1991; Motokura et ah, 1991) 
are upregulated and interact specifically with either cdk4 or cdk6 (Matsushime et 
a l, 1992; Meyerson et al., 1994). The assembled cyclinD/cdk sub-unit then enters 
the nucleus where it must be phosphorylated by a cdk-activating kinase (cak) to be 
able to phosphorylate its target substrates (Sherr and Roberts, 1999). The 
phosphorylation of members of the pocket protein family by the cyclin/cdk 
complexes leads to the release of the E2F transcription factor, which induces genes 
involved in cell cycle progression and DNA synthesis.
One target for E2F is cyclinE, which forms a complex with cdk2 to produce a 
further level of phosphorylation of the pocket proteins and the complete induction 
of E2F and S-phase progression (Sherr, 2000). Up-regulation of cyclinD is under 
the control of mitogenic stimulus that, if  withdrawn, results in removal from the
cell cycle. CyclinE induction by E2F correlates with the passing of the restriction 
point in late Gl that commits the cell to divide beyond the control of mitogenic 
signals.
Given its crucial role in initiating cell cycle progi'ession, the cyclinD/cdk4/6 
complex is frequently mutated in many human cancers. CyclinD itself is 
overexpressed in many human cancers as a result of gene amplification (Sherr, 
1996). The cyclinD gene, located at position 13 on the long arm of chi'omosome 11 
(1 lq l3), is amplified in a variety o f tumours including squamous cell carcinomas of 
the head and neck, esophageal careinomas, bladder cancer and primary breast 
carcinomas (Hall and Peters, 1996). Work by Wang et al. (1994) showed that the 
targeted overexpression of cyclinD in mannnary epithelial cells in mice led to 
tumour formation. This work suggests that cyclinD directly contributes to 
oncogenesis.
The cdks that cyclinD binds and activates, cdk4 and cdk6, are also misregulated in 
many types of human cancer. Cdk4 is amplified and overexpressed in a range of 
tumours including gliomas (Schmidt et al., 1994; Sonoda et al., 1995), sarcomas 
(Kliatib et al., 1993; Wunder et al., 1999) and breast cancers (An et al., 1999). In 
lymphoid tumours (Chilosi et a l, 1998), gliomas and squamous cell carcinomas 
(Costello et al., 1997) the cdk6 gene is amplified, whilst point mutations in both 
cdk4 and cdk6 have been reported in melanomas (Zuo et al., 1996) and 
neuroblastoma cell lines (Easton et al., 1998). Such point mutations lead to the
inability of the cdks to bind to their inhibitors, the INK4 family (Ranade et a l, 
1995).
CyclinE, and its catalytic partner, cdk2, have both been identified as having a role 
in tumourigenesis. Overexpression of cyclinE and cdk2 has been reported in 
colorectal carcinomas (Kitahara et ah, 1995) whilst cyclinE amplification has also 
been observed in bladder cancer (Richter et a l,  2000), esophagael adenocarcinomas 
(Lin et al., 2000) and non-small cell lung cancers (Mishina et al., 2000).
Whilst the cyclin/cdk complexes positively regulate cell cycle progression, the 
cyclin dependent kinase inhibitors (cdkis) act to prevent cell cycle progi'ession. The 
cdkis comprise two families: the rMK4 family (INliibitors of cyclin dependent 
Kinase 4) and the Cip/Kip family. The INK4 family consists of plb^^'^^^, p i 5^ ^^ '"'^ ’^ , 
plgiNK4c p^ i^NK4d and Robcrts, 1999). This group specifically inhibits
the actions of the cyclinD dependent kinases, cdk4 and cdk6. The Cip/Kip family of 
cdkis are more general acting and are able to prevent the catalytic activity of the 
cyclinD-, E- and A-dependent kinases. This family consists of p21* '^^  ^ p27^ '^'’^  and 
p 5 7 Kip2  and Roberts, 1999).
Not suiprisingly, given their intricate role in the negative regulation of the 
cyclin/cdk complexes, the frequency of mutations within the cdkis is extremely 
high within the context of cancer. Homozygous deletions of the p i locus have 
been found in gliomas, mesotheliomas, acute lymphocytic leukemias and sarcomas
(SheiT, 1996). p i f u n c t i o n  is also lost in many sporadic cancers (Ruas and 
Peters, 1998). Surprisingly, work by Zindy et al. (2000) revealed that the dismption 
of both pl5^^ '^ '^  ^ and did not result in tumourigenesis in mice however
plSi^K4c in mice causes pituitary tumours (Franklin et al., 1998).
In contrast to the INK4 family, the Cip/Kip family does not appear to be mutated to 
the same degree in human cancers. Since neither copy of the gene was found to be 
deleted in tumours, the Kip gene was not thought to act as a tumour suppressor. 
However, work by Fero et al. (1998) has shown that the gene need only be 
mono allelic to contribute to neoplasia. This is unlike most tumour suppressors, 
which are usually homozygously inactivated. Indeed, reduced p27^ '^ '^  ^ levels are 
observed in primary breast cancer (Catzavelos et al., 1997).
1.1.3 The Rb/E2F Pathway in Cancer
The E2F protein was the first cellular protein identified that bound to the 
retinoblastoma protein (pRB) (Bagchi et al., 1991; Chittenden et al., 1991; Bandara 
and La Thangue, 1991; Helin et al., 1992; Kaelin et al., 1992). There are six 
members of the E2F family (E2F1-6) and in a heterodinieric complex with a 
member of the DP family (DPI-3), E2F can transcriptionally activate genes with an 
E2F site. Such genes are essential for DNA synthesis and cell cycle progression.
E2F activity is primarily regulated by the pocket proteins. This family consists of 
pRB, p i07 and p i30. E2F/DP heterodimers guide the pocket proteins to E2F 
binding site-containing promoters where they fonn complexes with proteins that 
can induce the down-regulation of E2F ti'ansactivation by: (1) the direct shielding 
of the E2F transactivation domain; and (2) the modification of the chromatin 
enviromnent (Muller and Helin, 2000).
As described above, the sequential phosphorylation of the pocket proteins by the 
cyclin/cdk complexes leads to the hypeiphosphorylation of the pocket proteins and 
the release of E2F. It has now been firmly established that the plô^^"^^, cyclinD, 
cdk4, pRB pathway (Figure I.IB) is fi*equently mutated in human cancers. The 
biochemical connection between these molecules as well as the fact that the 
deregulation of one component often alleviates the need for deregulation of another 
has led to the assumption that the mutation of this pathway is a prerequisite for 
oncogenesis (Muller and Helin, 2000). Interestingly, tumours canying pRB 
mutations do not tend to exhibit mutations in any of the other components of this 
pathway.
Inactivation of pRB is frequently obseiwed in tumour development. pRB mutation 
is commonly seen in small-cell carcinomas of the lung (Hall and Peters, 1996). 
Somatic mutations in pRB also contiibute to osteosarcomas, renal cell carcinomas 
and bladder carcinomas (Hickman et al., 2002), Although work by Suzuki et al. 
(1999) pointed to a role for E2F1 amplification in gastric and colorectal
carcinomas, E2F is not a frequent target for deletion or amplification in human 
cancers. Presumably, E2F deletion or amplification does not provide tumours with 
a significant proliferative advantage.
1.1.4 The ARF/p53 Pathway in Cancer
The INK4a gene encodes a second potent tumour suppressor named p i9 ^ ^  (pl4^^^^ 
in humans) (Quelle et al., 1995). This gene is located on the short ami of 
chromosome 9 (9p21). The transcripts encoding these distinct genes are driven by 
two independent promoters and encompass a unique first exon (exon l a  and exon 
Ip) followed by two common exons, E2 and E3. These exons are translated using 
different open reading frames and hence, the complete lack of amino acid 
homology between and p i4 ^ ^  (Figure I.IC) (Ortega et a l, 2002).
ARF can block the actions of MDM2 (HDM2 in humans) by preventing the 
degradation of its primary target, the p53 tumour suppressor protein (Ortega et al., 
2002). p53 is a transcription factor that induces cell cycle arrest or apoptosis, 
depending on the biological setting (Sherr, 2000). MDM2 is a proto-oncogene 
product that neutralises the actions of p53 by binding to, and inhibiting, its 
transactivation domain (Momand et al., 1992; Oliner et al., 1992).
The introduction of ARF into cells causes cell cycle arrest in a p5 3-dependent 
fashion, suggesting that ARF acts upstream of p53 (Kamijo et al., 1997). Cells 
lacking p53 have elevated levels of ARF and réintroduction of p53 lowers ARF 
levels (Kamijo et a l, 1998; Stott et a l,  1998). This suggests that p53 controls the 
level of ARF by a negative feedback mechanism. By blocking the effects of 
MDM2, ARF can allow p53 transcription (Kamijo et a l,  1998; Stott et a l, 1998), 
prevent p53 ubiquination (ITonda and Yasuda, 1999) and block p53 export to the 
cytoplasm (Tao and Levine, 1999; Zhang and Xiong, 1999).
Work by Bates et a l  (1998) showed that E2F1 could induce the expression of 
p i4 ^^ . Following the release of E2F activity from RB, E2F1 upregulates ARF 
expression which leads to the inliibition of MDM2 activity on p53. p53 stabilisation 
then leads to the targeting of genes involved in either cell cycle arrest or apoptosis. 
p21, a p53 target, can induce hypophosphorylated RB which then inhibits E2F 
activity, hi this way, ARF links the RB/E2F pathway with p53 (Figure LID).
The p53 gene is the most frequently mutated gene in human cancer (Nigro et a l, 
1989; Levine et a l, 1991; Greenblatt et a l, 1994). The nature of these genetic 
changes in cancer cells is most commonly a mis-sense mutation in one allele, 
producing a faulty protein that is then observed at high concentrations in these 
cells, followed by a reduction to heterozygosity (Levine, 1997). Around one third 
of sarcomas inactivate p53 by the amplification of MDM2 (Oliner et a l, 1992). 
ARF mutation is also frequently observed in human cancers. Work by Kamijo et al.
(1999) showed that mice lacking ARP are prone to sarcomas, lymphomas, 
carcinomas and tumours of the central nervous system whilst inactivation of the 
ARF promoter by méthylation occurs in carcinomas and adenomas of the colon 
(Robertson et al., 1998; Esteller et al., 2000).
1.1.5 The Apoptotic Pathway in Cancer
Apoptosis, or programmed cell death, is a physiological process for killing cells 
that is critical for the correct development of multicellular organisms. Apoptosis is 
subject to genetic control (Ellis and Hoiwitz, 1986; Vaux et al., 1988) and 
abnonnalities in the process can lead to a variety of diseases including cancer 
(Strasser et al., 1990; McDonnell and Korsmeyer, 1991). Molecular changes 
induced during apoptosis include intemucleosomal DNA cleavage and 
randomisation of the distribution of phosphatidyl serine (PS) between the inner and 
outer leaflets of the plasma membrane. Morphological changes include chromatin 
condensation, cytoplasmic shrinlcage and plasma blebbing (Strasser et al., 2000).
Distinct pathways that lead to apoptosis all converge on the activation of the 
caspases. These are a family of cysteine proteases that cleave substrates on the 
carboxyl side of an aspartate residue. The caspase family are essential for 
programmed cell death in all cells, regardless of their origin or the death stimulus 
(Strasser et al., 2000). Initiator caspases such as -8 and -9 induce an increase in
1 0
caspase activity by activating the effector caspases-3, -6 and -7 (Nicholson and 
ThombeiTy, 1997). The effector caspases then cleave essential cellular proteins 
such as DNA repair enzymes, MDM2 and protein kinase ô (Nicholson and 
Thoraberry, 1997; Thomberry and Lazebnik, 1998).
Cells can initiate apoptosis via two distinct mechanisms (Figure TIE). The first 
involves the receptor-mediated death-signalling pathway that triggers the activation 
of caspase-8 by cleaving its precursor, pro-caspase-8. This occurs through the 
interaction of members of the tumour necrosis factor (TNF) ligands with their 
receptors (TNF-R). CD95 (also called Fas or APO-1) as well as other members of 
this family are referred to as the death receptor family (Strasser et ah, 2000).
Activated caspase-8 then causes the cleavage, and activation, of the effector pro- 
caspases-3, -6 and -7. The second pathway is via the release of cytoclrrome c from 
the mitochondria via the actions of either caspase-8 or the Bcl-2 family. 
Cytoclrrome c interacts with both pro-caspase-9 and Apaf-1, creating the 
apoptosome. This causes the cleavage of pro-caspase-9 to caspase-9, which can 
then cleave, and activate, the effector caspases. Members of the Bcl-2 family 
heavily influence this second pathway (Rich et aL, 2000).
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The Bcl-2 family consists of both pro-and anti-apoptotic members that focus much 
of their efforts at the mitochondria, and they play a pivotal role in deciding whether 
a cell will live or die (Gross et aL, 1999). The family consist of Bcl-xs, Bad, Bak 
and Bax that stimulate apoptosis and Bcl-2, MCL-1 and Bc1-xl that inliibit the 
process (van Hemert., 2001). Both Bcl-2 and BcI-xl are bound, and inactivated, by 
Bad (Yang et a l, 1995; Mok et a l, 1999) which leads to cytochrome c release and 
cell death.
Indeed, work by Oltvai et a l  (1993) suggested that the ratio between the pro- 
apoptotic and anti-apoptotic members of the family helped to determine the 
susceptibility of cells to death signals. The anti-apoptotic members o f the family are 
found as integral membrane proteins, localised to the membranes of the 
mitochondria, endoplasmic reticulum and the nucleus (Krajewski et a l,  1993). In 
contrast, a substantial fraction of the pro-apoptotic members are found localised to 
the cytosol or the cytoskeleton prior to a death signal (Gross et a l,  1999).
Cell death signals lead to the activation of the pro-apoptotic members of the family 
(Zha et a l, 1996) which then inactivate the mitochondria-bound anti-apoptotic 
members. These death signals can be extra-cellular, such as interleukin-3 
deprivation, or intra-cellular such as p53 transcription of pro-apoptotic target genes 
(Gross et a l, 1999). This leads to cytoclnome c release, the fonnation of the 
apoptosome, the activation of the effector caspases and, ultimately, cell death.
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With such potent mechanisms in existence to obliterate displaced cells, it is no 
surprise that suppression of apoptosis is high on the list of acquired attributes in 
cancer cells (Evan and Vousden, 2001). The survival signals, insulin-like growth 
factor (IGF)-l and IGF-2, are known to be mutated in human cancers (Yu and 
Rohan, 2000) whilst both Bcl-2 and Bc1-xl , members of the anti-apoptotic family 
of Bcl-2, are overexpressed in several tumour types (Evan and Vousden, 2001). 
Work by Soengas et a l  (2001) also identified loss of Apaf-1 in malignant 
melanomas.
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Figure I.IA: The Mammalian Cell Cycle
Gapl (Gl), Synthesis-phase (S-phase), Gap2 (G2) and Mitosis (M) are the 
traditional subdivisions of the cell cycle. G l, S-phase and G2 constitute the 
interphase portion of the cell cycle whilst mitosis involves separation of the 
duplicated DNA and finally, cell division. G l and G2 provide additional time for 
the cell to grow, S-phase involves duplication of the cells DNA whilst during 
mitosis the cells microtubules foim the spindles that separate the duplicated 
clnomosomes. Cells can enter a resting state called GO if  they have not committed 
to duplicating their DNA. They can remain here indefinitely until they decide to re­
enter the cell cycle. Up until the restriction point the cell is under the control of 
mitogenic growth factors. After this point in late G l the cell is committed to 
dividing unless cellular insults occur. If this happens the cell can initiate a cell cycle 
aiTest at either the Gl/S or G2/M boundaries. Red lines indicate an inhibitory 
effect. The figure is adapted from Alberts et aL (1994), Figure 17-3.
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Figure I.IB: The pRB/E2F Pathway
Mitogenic stimulation induces the expression of the D-type cyclins which then 
complex with cdk4/6. This causes an induction in E2F activity, and subsequent S- 
phase entry, tlirough the phosphorylation of pRB. The cyclin-dependent inhibitors 
(ckis) can block the induction of E2F by preventing the activity of the cdks. 
Analysis of human tumours has shown that deregulation of only one portion of the 
pathway is enough to confer neoplastic potential. Blue lines indicate stimulatory 
effect; red lines indicate inhibitory effect. The figure is adapted from Nevins, 
(2001), Figure 1.
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Figure I.IC: The ARF-INK4a Gene
The transcripts encoding these distinct genes are driven by two independent 
promoters and encompass a unique first exon (exon l a  and exon Ip) followed by 
two common exons, E2 and E3. These exons are translated using different open 
reading frames and hence, the complete lack of amino acid homology between 
pj i^NK4a p i4 ^^ . Common mutations in human cancers are indicated with red
aiTOWS whilst promoter méthylation sites are shown as blue circles. The figure is 
adapted from Ortega et aL (2002), Figure 4.
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Figure I.ID: 014'^ "^ " Links E2F With p53
Following the induction o f E2F1, is upregulated. p l 4 ' '^  can subsequently
block the negative activity of MDM2 on p53. This leads to the stabilisation of p53 
and either an arrest in the cell cycle or the induction of apoptosis. The up-regulation 
of p21, a p53 target gene, leads to the inhibition of the cyclin/cdk complexes and 
the subsequent inhibition of E2F activity. Blue lines indicate stimulatory effect; red 
lines indicate inhibitory effect. The figure is adapted from Nevins, (2001), Figure 2.
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Figure I.IE: Cells can initiate apoptosis via two distinct 
mechanisms
The initiation of the apoptotic response can occur through two different pathways. 
The first involves the receptor-mediated death-signalling pathway that triggers the 
activation of caspase-8 by the cleavage o f its precursor, pro-caspase-8. Caspase-8 
can then directly initiate apoptosis by the activation of effector caspases, caspase-3, 
“6 and -7. The mitochondrial pathway involves the release of cytochrome c by the 
effects of caspase-8 or the actions of the Bcl-2 family. Cytochrome c interacts with 
both pro-caspase-9 and Apaf-1, creating the apoptosome. This causes the cleavage 
of pro-caspase-9 to caspase-9, which then induces the activation of the effector 
caspases. Blue lines indicate a stimulatory effect. The figure is adapted from Gross 
et al. (1999), Figure 3.
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1.2: The E2F Proteins 
1.2.1: Introduction
In mammalian cells the E2F family of transcription factors plays a crucial role in 
the regulation of genes that are involved in controlling cell proliferation, DNA 
synthesis and apoptosis (Figure 1.2A). Work by Kovesdi et al. (1986) identified 
E2F as a protein that was able to bind to, and activate, the adenoviral E2 gene 
promoter due to the actions of the adenoviral E l A product (DeGregori, 2002). La 
Thangue and Rigby, (1987) then identified a protein with the same consensus 
DNA-binding site as E2F that was down regulated in F9 (EC) stem cells during 
differentiation. They called this DRTFl (differentiation-regulated transcription 
factor 1). DRTFl and E2F were subsequently identified as being the same protein.
The E2F family consists of six E2F members (E2Fs 1-6) that form heterodimers 
with a DP partner (DPs 1-3) (Helin et aL, 1992; Ivey-Hoyle et aL, 1993; Lees et aL, 
1993; Beijersbergen et aL, 1994; Ormondroyd et aL, 1995; Zhang and Chellappan., 
1995; Rogers et aL, 1996; Morkel et aL, 1997; Cartwright et aL, 1998; Trimarchi et 
a l,  1998) [Figure 1.2B(i)]. E2Fs 1-3 are traditionally seen as the ‘activating’ E2Fs 
with E2Fs 4-6 seen as being ‘repressive’ E2Fs [Figure 1.2B(ii)]. E2F6 is unique 
since it does not contain a transcriptional activation (^raw^'-activation) domain 
(Trimarchi et aL, 1998). The E2F portion of the family recognises, and is able to 
bind to, the DNA promoter sequence -TTTCGCGC- (Lees et aL, 1993; Buck et aL, 
1995; Zhang and Chellappan., 1995). The DP partner offers co-operative binding to 
the DNA (Dyson, 1998). In the literature DP2 refers to the human fonn and DP3 to
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the mouse form of what is recognised as being the same protein. Work by Rogers et 
al. (1996) identified human DP2 as an E2F binding protein from a yeast two-hybrid 
screen of a HeLa cell library. DP3 was identified from a murine library. The protein 
consists of four splice variants of the same gene, termed a , p, y and ô, determined 
by their various N-terminal organisations (Ormondroyd et aL, 1995) [Figure 
1.2B(i)]. The a  and 5 splice variants of DP2/3 are nuclear due to an N-teiininal bi­
partite NLS whereas p and y are cytoplasmic since they lack the NLS (de La Luna 
et aL, 1996). In vitro at least, any DP member can fonn a complex with any E2F, 
suggesting a potentially wide aiTay of E2F/DP complexes in vivo (Dyson, 1998).
E2F can induce the expression of genes whose protein products are essential for 
DNA synthesis such as dihydrofolate reductase, thymidylate synthase and 
thymidine kinase (DeGregori, 2002). E2F is also able to transcriptionally activate a 
wide variety of genes involved in the cell cycle including cyclinE, cyclinA, cdc25A 
and the retinoblastoma protein pRB (DeGregori, 2002), Its association with pRB 
inhibits E2F activity.
1.2.2: The Role of E2F as a Transcription Factor
Although E2F and many other sequence-specific transcription factors are essential 
for the processing of DNA into mRNA, it requires many more protein factors for 
effective transcriptional control. Indeed, mRNA synthesis by RNA polymerase II 
(RNA pol II), is dependent on a wide an'ay of additional factors including TFIIA,
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B, D, E, F and H which, together, fonn the pre-initiation complex (PIC). These 
general transcription factors (GTFs) also assist in DNA unwinding as well in the 
transition from transcription initiation to RNA transcript elongation (Naar et al., 
2001).
This apparatus, referred to as the basal transcriptional machinery, is sufficient to 
mediate basal transcription. However, high levels of regulated, gene selective 
transcriptional activity additionally requires the action of sequence-specific 
activators such as B2F (Naar et al., 2001). E2F is able to bind to the general 
transcription factor TFIID, which binds to the TATA nucleotide sequence found in 
many eukaryotic promoters (Horikoshi et a l, 1988).
TFIID is comprised of the TATA binding protein (TBP) and other TBP associated 
factors (TAFs) which act as adapters to bridge the gap between sequence-specific 
transcription factors such as E2F, and the basal transcriptional machinery. The 
multi-subunit TFIID works together with TFIIA and TFIIB to assemble the 
initiation complexes at eukaryotic promoters (Andel et al., 1999). The GTFs and 
then RNA pol II can then bind to the DNA and the downstream initiator element. 
Figure 1.2C highlights the organisation of the PIC.
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1.2,3: The pRb/E2F Association
pRB was the first tumour suppressor to be identified and it is absent or mutated in 
at least one third of human cancers (Trimarchi and Lees, 2002). pRB is the 
prototype member of a family of proteins, referred to as the pocket proteins, that 
includes p i 07 and p i30 (Stevens and La Thangue, 2003). pRB preferentially binds 
E2Fsl-3 with pl07 and pl30 preferentially binding E2F4 and E2F5 respectively 
(Ginsberg et al., 1994; Vairo et al., 1995). Work by Qin et al. (1992) showed that 
the transcriptional activity of E2F was inliibited by its association with pRB and 
that this resulted in cell cycle arrest at G l.
The pocket domain of pRB (amino acids 395-876) interacts with an eighteen amino 
acid sequence within the C-terminal /ra^^'-activation domain of E2F, blocking 
E2F’s transcriptional activity (Helin et al, 1993). This allows pRB to block E2F 
site-dependant ^ra?î5-activation without affecting the DNA binding ability of E2F 
(Zamian and La Thangue, 1993; Helin et al., 1993). Work by Hateboer et al. (1996) 
and Hofhiann et al. (1996) showed that pRB binding protects E2F from degradation 
by masking potential ubiquination sites within the z^raM '^-activation domain of the 
protein.
Physiologically, thi'ee types of E2F complex can exist (Figure 1.2D). The first 
contains ‘free’ E2F as a result of hyperphosphorylated pocket proteins. This type of 
complex is a potent activator of target genes and cell cycle progression. The second 
type of E2F complex exists as an inliibitor complex. Hypophosphorylated pocket
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proteins bind to, and prevent, E2F activity thereby acting as an inliibitor of E2F- 
responsive genes. Recent work by Brehin et aL (1998) and Dahiya et aL (2000) has 
now shown that pRB can also actively recruit HDACs (Histone DeACetylases). 
The HDACs are a family of enzymes that remove acetyl groups from lysine 
residues in the amino terminus of histoires, thereby influencing the cliromatin 
structure of target genes. The hypoacetylation of lysine residues by HDACs then 
leads to the méthylation of these residues by histone methyltransferases (HTMases) 
such as SUV39H1. pRB-dependent transcriptional repression also involves 
recruitment of polycomb group (PcG) protein-containing complexes which can 
induce changes in cliromatin packaging (DeGregori, 2002). pRB can also recruit 
BRGl and HBRM, two ATPase components of the human SWFSNF chi'omatin- 
remodelling complex. This results in nucleosome remodelling. This third type of 
E2F complex can therefore exist as an active repressor complex that influences 
long term gene silencing.
1.2.4: The Regulation of E2F Activity
During GO and early Gl pRB is hypophosphorylated which results in E2F binding. 
Extra-cellular mitogenic growth factors then cause the activation of the cell-cycle- 
dependant kinase complexes cyclinD/cdk4/6 which phosphorylate pRB, causing the 
release of E2F. E2F can then induce the transcription of the cyclinE gene, which 
forms a complex with cdk2 causing a further increase in hyperphosphorylated pRB. 
This creates more ‘free’ E2F which drives the cell tlmough the Gl/S boundaiy, into
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the DNA replication phase. Up until the expression of the cyclinE/cdk2 complex 
the cell is under the control of the mitogenic factors and can exit the cell cycle at 
any time. Upon the expression of the cyclinE/cdk2 complex the cell passes a 
restriction point in late Gl after which it is coimnitted to undergo DNA replication 
and is no longer sensitive to growth factor signalling (Trimarchi and Lees, 2002). 
After this point the cell cycle can only be halted tlirough cellular insults such as 
DNA damage. As mentioned above, the activity of the cyclin/cdk complexes can be 
blocked by the cyclin dependent kinase inhibitors (cdis), which results in 
hypophosphorylated pRB and inactive E2F. Figure 1.2E provides an overview of 
the actions of the cyclin/cdk complexes and cdkis on E2F function throughout the 
cell cycle.
The importance of pRB in vivo is highlighted by the fact that pRB-deficient mice 
die between embryonic day (E) 13.5 and 15.5 with defects in fetal liver 
haematopoiesis, neurogenesis and lens development that results from a combination 
of inappropriate cell cycle entry and apoptosis (Trimarchi and Lees, 2002). In 
contrast, p i07"^ " and p i30'^ " mice survive to teim and show no increase in the 
incidence of tumour formation. This suggests that both p i07 and p i30 act 
independantly of pRB. However, pl07'^7pl30'^“ mice are embryonic lethal which 
suggests functional redundancy between these two proteins (Stevens and La 
Thangue, 2003).
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As well as the level of control that the pocket proteins exert over E2F, other factors 
can impinge on E2F activity. Whereas the cycliiiD/cdk4 and cyclinE/cdk2 
complexes have a positive influence on E2F activity, the cyclinA/cdk2 complex has 
a negative effect. During S-phase cyclinA/cdk2 binds to E2F1. This results in the 
phosphorylation of DPI causing a loss of E2F DNA binding affinity (Ki*ek et aL,
1995). Work by Xu et aL (1994) and Guida and Zhu, (1999) showed that the 
cyclinA/cdk2 complex could phosphorylate E2F1 at serine-375 resulting in a 
reduced DNA binding ability of E2F1.
To allow correct S-phase induction, E2F activity must be tightly regulated. This is 
achieved through the ubiquitin protein ligase SCF^^^ (Marti et aL, 1999). During 
S-phase a component of the SCF complex, p45^^^^, binds to E2F1 and promote its 
degradation via the ubiquination process (Marti et aL, 1999). Recent work by Lin et 
aL (2001) showed that this effect could be prevented by the DNA damage 
responsive elements ATM/ATR. These kinases can phosphorylate serine-31 in 
E2F1 which prevents the binding of p45^ "^^ ^^  and the subsequent degradation of 
E2F1 (Lin et aL, 2001).
Upon dissociation of pRB, E2F1 becomes the target of the p300/CBP family of 
coactivator proteins, which bind in the C-teiininal of the protein (Tronche et aL,
1996). This family has an intrinsic histone acetyl transferase (HAT) activity. Work 
by Martinez-Balbas et al. (2000) showed that the p300/CBP-associated factor
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(P/CAF) could acetylate E2F1 within its DNA binding domain. This activity 
enhanced the stability as well as the DNA binding activity of E2F1.
1.2.5: The p53/E2F Pathway
The p53 protein plays a key role in cellular decisions to either arrest the cell cycle, 
allowing the repair of damaged DNA, or to commit to cell death (Sears and Nevins, 
2002). The accumulation of p53 is negatively regulated by the E3-ligase, MDM2 
(Shen' and Weber, 2000). The activity of MDM2 is negatively regulated by p l4^ ’^*" 
(Sherr and Weber, 2000) which is a direct target for E2F1 (DeGregori et a l, 1997). 
Stabilisation of p53 results in the transcriptional activation of p53 target genes 
involved in blocking cell cycle progression, including p21 (el-Deiry et al., 1993). 
p21 is able to block the activity of cyclinD/cdk4, cyclinE/cdk2 and cyclinA/cdk2 
(Levine, 1997). This then leads to hypophosphorylated pRB and inactivation of 
E2F activity. The induction of p i4^^^ by E2F1 and the subsequent expression of 
p21, via p53, highlight how the pRb/E2F pathway directly comiects to p53.
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1.2.6; The ‘Activating’ E2Fs
Recent work by Wu et al. (2001) has shown that E2Fs 1-3 are essential for cellular 
proliferation since the combined ablation of these proteins prevents S-phase entry. 
Work by Lukas et al. (1996) showed that overexpression of these E2Fs could 
overcome the growth inliibitory effects of p i 6.
E2F1 was originally cloned due to its ability to bind pRB (Helin et al., 1992; Kaelin 
et a l, 1992; Shan et al., 1992). E2F1 was subsequently shown to bind to DNA in a 
DP-dependant manner, and the resulting complex was shown to be a potent 
transcriptional activator of E2F-responsive promoters (Trimarchi and Lees, 2002). 
Subsequent work by Ivey-Hoyle et al. (1993) and Lees et al. (1993) identified E2F2 
and E2F3. Both E2F2 and E2F3 are highly homologous to E2F1 within the area of 
the DNA binding, DP dimérisation and pRB binding domains. E2Fs 1-3 
preferentially bind to pRB and all are able to potently induce the expression of 
genes involved in the cell cycle and apoptosis. As such, E2Fs 1-3 have been 
classified as ‘activating’ E2Fs.
In normal cells the ‘activating’ E2Fs are specifically targeted and inliibited by pRB 
but not by p i07 or p i 30. The release of E2Fs 1-3 from pRB occurs at mid-late G1 
and this activation coiTelates closely with the activation of E2F target genes and the 
potent induction of S-phase. Indeed the functional inactivation of pRB in either 
embryonic tissues or tumours induces inappropriate proliferation (Trimarchi and 
Lees, 2002).
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The overexpression of E2F1, E2F2 or E2F3 is sufficient to cause quiescent cells to 
re-enter the cell cycle (Johnson et al., 1993; Qin et al., 1994; Lukas et a l, 1996). 
Work by Helin et al. (1992) and Lees et al. (1993) showed that E2Fs 1-3 were 
potent transcriptional activators of E2F-responsive promoters. As well as having a 
critical role in proliferation, E2Fs 1-3 have potent apoptotic effects as well, 
mediated through both p53-dependant and p53-independent pathways (Qin et a l, 
1994; Shan and Lee, 1994; Hsieh et a l,  1997; Phillips et a l, 1999). The induction 
of apoptosis via E2F usually requires the transcriptional activity of the molecule 
however there is still considerable debate over the pathways that are responsible 
(Trimarchi and Lees, 2002).
With regards the p5 3-dependant pathway, the current model is that E2F1 induces 
cell death via the up-regulation of the ARE gene which is a known E2F target gene 
(DeGregori et al., 1997; Bates et al., 1998). pl4*^^ can target the inhibitory effects 
of MDM2 on p53 resulting in the stabilisation of p53 and the up-regulation of p53 
pro-apoptotic genes such as Bax (SheiT and Weber, 2000). Recent work has now 
pointed to the fact that E2F1 can induce apoptosis in a p5 3-dependant manner in 
the absence of p i 9"^ ^^  (Tolbert et al., 2002). This indicates alternative mechanisms 
for E2F1 induced apoptosis via p53.
Recent work by Irwin et al. (2000) has shown that E2F1 can induce the expression 
of the p53 homologue, p73. This points towards a role for E2F in p53-independent 
apoptosis. Indeed the Apafl gene, which is involved in cytochrome c release horn
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the mitochondria has also now been identified as a transcriptional target for E2F1 
(Moroni et aL, 2001). As well as a transcriptional role for E2F induced apoptosis 
there may be active repression by E2F on suiwival signals such as the tumour- 
necrosis factor receptor (TNFR) (Phillips et aL, 1999).
Despite this there is still some debate as to whether E2Fs 2 and 3 play as significant 
a role in apoptosis as E2F1. Work by Degregori et al. (1997) suggested that the 
induction of apoptosis was a specific property of E2F1 however Ziebold et al. 
(2001) showed that mutation of E2F3 in pRB-deficient embryos was sufficient to 
suppress not only cellular proliferation but also p53-dependant and p53- 
independant apoptosis. Indeed this group showed that the degi'ee of suppression 
exceeded that seen when E2F1 alone was lost, suggesting that E2F3 can induce 
apoptosis independently o f E2F1. It therefore remains to be seen whether only 
E2F1 can induce apoptosis or whether indeed either, or both, E2F2 and E2F3 are 
equally as potent at inducing cell death.
Mutant mouse strains have also been used to investigate the role of the activating 
E2Fs in nonnal development (Trimarchi and Lees, 2002). Whereas a significant 
proportion of E2F3’^ ' mice die in utero (Humbert et al., 2000), E2F1'' '^ mice are 
viable but display an excess of T cells (Garcia et al., 2000) and develop tumours in 
older mice (Yamasaki et al., 1996), suggesting that E2F1 plays a role in tumour 
suppression. At present many investigators believe that E2F1 acts as a tumour 
suppressor through its ability to induce apoptosis (Trimarchi and Lees, 2002).
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1.2.7: The ‘Repressive’ E2Fs
The ‘repressive’ E2Fs include E2Fs 4-6. E2F4 and E2F5 were eloned by virtue of 
their association with pocket proteins or DPI (Stevens and La Thangue, 2003). 
Since both E2F4 and E2F5 lack the intrinsic NLS seen in E2Fs 1-3 they require to 
be coinplexed with a pocket protein to enter the nucleus (Allen et aL, 1997; Verona 
et aL, 1997) and are seen as repressors of E2F-responsive genes. As well as their 
unique organisation (Figure L2B) E2Fs 4-5 differ remarkably from E2Fs 1-3 in 
their expression. Whereas the levels of E2Fs 1-3 peak at the Gl/S boundary, both 
E2F4 and E2F5 are constitutively expressed tlnoughout the cell cycle with the 
majority of E2F4/5 pocket protein complexes present in GO and early G1 (Dyson, 
1998). Since these complexes associate with FlDACs in vivo, E2F4 and E2F5 are 
thought to be crucial for mediating the transcriptional repression of E2F-responsive 
genes (Trimarchi and Lees, 2002).
However, work by de la Luna et al. (1996) showed that E2F4 and E2F5 could be 
imported into the nucleus in a transcriptionally active state via their association 
with the NLS-containing a  or ô splice variants of DP3. This suggests that the 
choice of DP partner in the E2F4/5 heterodimer can have an influence on the 
presence of transcriptionally active E2F4 or E2F5 in the nucleus (de la Luna et al.,
1996). Indeed, work by Loughian and La Thangue, (2000), showed that both E2F4 
and E2F5 could induce apoptosis. This was dependent on both the nuclear 
accumulation and the transcriptional activity of the E2F complex.
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Also, work by Moms et al. (2000) showed that the cyclinE/cdk2 complex could 
phosphorylate E2F5 within its ^ran^s-activation domain, which augmented the 
binding of the p300/CRE co-activator protein. This resulted in an increased 
stimulation of E2F-responsive genes in late Gl. This study implies a positive 
autoregulatory mechanism for E2F-dependent transcription and supports the notion 
that both E2F4 and E2F5 play a role in the activation of target genes (Stevens and 
La Thangue, 2003).
The choice of pocket protein partner also differs significantly between the 
‘activating’ and ‘repressing’ E2Fs. E2Fs 1-3 are specifically regulated by pRB 
whereas E2F4 associates with each of the pocket proteins at various point in the 
cell cycle and E2F5 is specifically regulated by p i30 (Trimarchi and Lees, 2002). 
Subsequent analysis of E2F-responsive promoters such as cdc2 and E2F1 showed 
that the levels of transcription from these promoters rose significantly during 
GO/Gl when these sites were mutated (Dalton, 1992; Hsiao et al., 1994).
Subsequent in vivo ChfP analysis by Takahashi et al. (2000) and Wells et al. (2000) 
has shown that the promoters of many E2F-responsive genes are occupied by 
E2F4/pl07 and E2F4/pl30 complexes during GO/GL As cells progress towards late 
G l, the levels of the E2F4/pl07 and E2F4/pl30 complexes that are associated with 
the E2F-responsive promoters declines, and the ‘activating’ E2Fs seem to replace 
the ‘repressing’ complexes on these promoters. Sigiifrcantly, the decrease in 
binding of E2F4 to E2F sites coiTelates with the dissociation of E2F4/DP
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complexes, together with the relocalisation of E2F4/DP to the cytoplasm (Stevens 
and La Thangue, 2003).
E2F gene knockouts in mice have revealed distinct biological roles for the 
repressive E2F complexes. E2F4'^’, E2F4'^" and E2F5‘^ ', pl07'^' or pl30'^' MEFs all 
have defects in exiting the cell cycle in response to a variety of gi'owth arrest 
signals such as p l6  overexpression and contact inhibition (Trimarchi and Lees,
2002). Despite this none of these MEFs fail to respond to gi'owth signals indicating 
that loss of the ‘repressive’ E2Fs impairs only the repression and not the activation 
of E2F-responsive genes, and therefore the ability to exit the cell cycle (Trimarchi 
and Lees, 2002).
The ‘repressive’ E2Fs also seem to play a critical role in differentiation. Work by 
Persengiev et al. (1999) showed that the differentiation of neuronal precursors 
could be induced by E2F4 overexpression. The primary defects in E2F4'^' mice are 
hematopoietic, craniofacial and intestinal defects whilst E2F5'^' mice are perinatal 
lethal with hydrocephalus (Humbert et al., 2000; Rempel et al., 2000; Lindeman et 
al., 1998). In contrast to the defects in the initiation of differentiation seen with 
E2F4"^“ and E2F5"^“ mice, both p i07"^ " and p i 30"^ ' mice show defects in the 
development of long bones. This is due to the failure of the chondi'ocytes to exit the 
cell eycle, before finally undergoing differentiation after several rounds of 
inappropriate cell division (Trimarchi and Lees, 2002).
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The most recently identified E2F is E2F6. This differs from the other E2Fs in that it 
lacks the C-terminal ^ra«.s-activation domain and therefore the capacity to form a 
complex with the pocket proteins (Morkel et aL, 1997). Unsurprisingly this has lead 
to the belief that E2F6 acts as an active repressor of E2F-responsive genes by 
occupying E2F promoters. Indeed, work by Ogawa et al. (2002) showed that E2F6 
can actively recruit chromatin-modifying proteins to E2F target genes, inducing 
gene silencing.
1.2.8: E2F and the DNA Damage Response
Several recent studies now point to a role for E2F in the DNA damage response 
pathway (Huang et a l,  1997; Lin et a l, 2001; Stevens et a l, 2003). Huang et al. 
(1997) showed that treatment of cells with ionizing radiation led to the up- 
regulation of E2F1 and subsequent cell death whilst most recently a report by 
Stevens et al. (2003) showed that the DNA damage responsive kinase, Clilc2, could 
phosphorylate E2F1 on serine-364. This led to the stabilisation, increased half-life 
and transcriptional activation of E2F1 as well as enhanced sub-Gl population, 
induced by E2F1. Whilst previous work by Lin et al. (2001) had shown that E2F1 
was phosphorylated by the ATM/ATR kinases, the work by Stevens et al. (2003) 
showed a further downstream effect by the Clilc2 kinase, which is activated in 
response to DNA damage by ATM/ATR.
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Interestingly, E2F1 has most recently been implicated in inducing an S-phase 
checkpoint by recmiting NBSl and the M R E ll recombination/repair complex to 
origins of DNA replication after DNA damage during S-phase (Cam and Dynlacht,
2003). Also, recent studies have shown that E2F targets may include p53, Chkl, 
PCNA and FENl, all of which are known to be intricately involved in the DNA 
damage response (Ishida et aL, 2001; Muller et aL, 2001; Polager et aL, 2002; Ren 
et aL, 2002).
Indeed not all the evidence for the role of E2F in the DNA damage response points 
to the role of the ‘activating’ E2Fs. Ren et al. (2002) have shown that E2F4 could 
induce the expression of a host of genes whose protein products are involved in 
DNA repair. All of these studies show a direct role for E2F in the DNA damage, 
DNA repair and apoptotic pathways.
1.2.9: E2F and Cancer
Given its central role in the control of proliferation, differentiation and apoptosis it 
is unsurprising that E2F is heavily implicated in tumourigenesis. Overexpression of 
the ‘activator’ E2Fs is sufficient to not only induce cell cycle entry but also to 
confer transfonning potential to primary cells (Cam and Dynlacht, 2003). Whilst 
much is known about the role of the ‘aetivator’ E2Fs in cancer, much less is known 
about the role that the ‘repressive’ E2Fs play. Work by Humbert et al. (2000) and 
Rempel et al. (2000) suggested that E2F4 does not act as a tumour suppresser. The
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role of E2F5 in tumour development is more difficult to assay since E2F5'^‘ mice 
die after six weeks. The compound loss of both E2F4 and E2F5 is difficult to study 
since the mice die as neonates (Cam and Dynlacht, 2003).
Inactivation of pRB by viral oncoproteins such as E l A, HPV E7, the large T 
antigen , or mutations within pRB itself, are enough to prevent the formation of the 
E2F/pRB complex, resulting in ‘free’ E2F. Many upstream regulators of E2F are 
also inactivated or amplified in tumours. Work by Wolfel et al. (1995) showed that 
a mutant cdk4 in human melanomas was constitutively active due to its inability to 
complex with the cdki, p i 6. Mutations that prevent the degradation of cyclinD can 
also ensure that pRB is in a pennanent state of hyperphosphorylation (Welcker et 
al., 1996).
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Figure 1.2A: E2F-Responsive genes
Tabular representation of a range of E2F-responsive genes involved in cell cycle 
regulation, DNA synthesis and apoptosis.
4 1
CELL CYCLE REGULATORS NUCLEOTIDE SYNTHESIS APOPTOSIS
Cyclin A Ribonucleotide Reductatase 1 ,2 Caspasc 3 ,7
Cyclin E
E2F1/2/3 Thymidine Kinase (TK) p73
DPI
Cdk2 Thymidilate Synthase (TS) Apafl
Cdk7
Cdc25A Deoxycytidine Kinase MAP3 Kinase 5
pRB
Pl07 Dihydrofolate Reductase (DHFR) ARF
Cdc2
Figure 1.2B: The E2F and DP Families
i. Schematical representation of the E2F and DP family members. E2Fs 1-3 
have an N-terminal cyelin A binding domain that allows the regulation of 
the DNA binding activity of these E2Fs during S-phase. E2Fs 4-6 have a 
truncated N-terminus and do not contain this domain. E2Fs 4-5 contain a 
nuclear export signal (NES) that is not present in E2Fs 1-3. E2Fs 1-5 
contain a C-terminal /raw5-activation domain with a pocket protein binding 
domain located within this region. E2F6 does not contain the trans- 
activation domain. The numbers represent the amino acid positions of the 
various domains within the family members.
Tlrree members of the DP family exist (DP 1-3). In the literature DP2 
human and murine DP3 are the same protein. Four splice variants of DP2/3 
exist: a , (3, 5 and y. a  and 6 are nuclear due to an N-terminal NLS. p and y 
are cytoplasmic, as is DPI, since they lack the NLS. The a  splice variant of 
DP2/3 has an extended N-terminus. The numbers represent the amino acid 
positions of the various domains within the family members. The figure is 
adapted from Stevens and La Thangue, (2003), Figure 2.
ii. Tabular representation of the properties of members of the ‘activating’ and 
‘repressing’ E2Fs as well as the DP family. The figure is adapted from 
Stevens and La Thangue, (2003), Table 1.
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E2Fs 1-3 N
E2Fs 4-5
I 16 28  6 7  108 110
»
■Lm
POCKET PROTEIN 
BINDING
CYCLIN A DNA TRANSACTIVATION
NLS BINDING BINDING/DIMERISATION DOMAIN
284 3 68  409 4 26  437
NES
rn
16 43  65  181 3 3 7  3 9 0  40 7  413
E2F6
50 222 281
DPI
DP2/3 a  
DP2/3 P 
DP2/3 Y 
DP2/3 5
N
Bi-Paiüte NLS
I I
104 109 113
101 1 2 0 1 2 5  129
1 59  64  68
1 59  64  68H
1 4 0  5 9  64  68
m
277
292
231
231
231
410
446
385
385
385
ii)
CHARACTERISTIC ACTIVATING E2Fs 
(E2FI/E2F2/E2F3)
REPRESSING E2Fs 
(E2F4/E2F5)
Pocket protein partner pRB pI07: E2F4 
pl30: E2F4/E2F5
Nuclear Localisation Signal 
(NLS)
Yes No
Nuclear Export Signal (NES) No Yes
Cyclin A Binding Yes No
Expression Gl/S Constitutive
Ability to induce apoptosis 
upon overexpression
Only E2FI No
Ability to override G1 arrest Yes No
Tumour suppressor function E2FI alone No
Figure 1.2C: The Pre-Initiation Complex
The PIC forms when the TBP subunit of TFIID [which comprises TBP and TBP 
associated factors (TAFs)] binds to the TATA sequence in eukaryotic promoters. 
The GTFs (TFIIA, B, D, E, F and H) then assemble, followed by RNA pol II. E2F 
is able to form a complex with TFIID and initiate sequence-specific transcription of 
target genes.
4 5
/
Figure 1.2D: The Types of Generic E2F Complexes
Representation of the three types of physiological E2F complex.
i. ‘Free’ E2F results from the sequential phosphorylation of the pocket 
proteins. This allows E2F to transactivate its target genes and to induee cell 
cycle progression.
ii. Inhibitory E2F complexes result from the binding of the pocket proteins to 
E2F. By binding within the C-terminal domain of E2F the pocket proteins 
act to inliibit the transcriptional activation of E2F-responsive genes.
iii. Repressive E2F complexes arise when the pocket proteins actively recruit 
proteins such as the HDACs, PcG, HTMases and members of the SWESNF 
family. This results in chromatin remodelling and long term gene silencing.
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Figure 1.2E: The Regulation of E2F by the cdks and cdkis
Overview of the regulation of E2F activity by the cyclin/cdk complexes and the 
cdkis during cell cycle progression. Up-regulation of cyclinD/cdk4/6 activity 
follows mitogenic stimulation. This results in low level phosphorylation of the 
pocket proteins, resulting in partial induction of E2F. CyclinE/cdk2 complexes then 
induce hyperphosphorylated pRB, resulting in ‘free’ E2F, which then drives the cell 
into S-phase. Once past the restriction point the cell is no longer under the control 
of mitogenic stimulation and must divide unless cellular stresses occur. During S- 
phase, phosphorylation of DPI and E2F1 by cyclinA/cdk2 results in the removal of 
the DP/E2F complex from the DNA. The activity of the cyclin/cdk complexes can 
be blocked by the indicated cdkis. Red lines indicate an inhibitory effect on cell 
cycle progression. Blues lines indicate a stimulatory effect.
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1.3: The 14-3-3 Proteins 
1.3.1: Introduction
In 1967 Moore and Perez described an acidic, and highly abundant brain protein, 
which they termed 14-3-3, based on the fraction number after DEAE-cellulose 
clmomatography and the position after starch gel electrophoresis (Moore and Perez, 
1967). 14-3-3 proteins have now been identified in all eukaryotic organisms with 
seven isoforms in mammals, fifteen in Arahadopsis Thcdiana and two in yeast 
(Rosenquist, 2003). hi mammals the isoforms are named p, e, r\, y, a, x and Ç [a 
and Ô are the phosphorylated forms of P and respectively (Aitken et a l, 1995)].
14-3-3s are involved in a wide range of biological processes including neuronal 
development, cell cycle control and apoptosis (Fu et a l, 2000) and bind a vast array 
of target substrates (Figure 1.3A). 14-3-3s can alter the activities of target proteins 
by sequestering them, relocalising them, confoimationally altering their functional 
activity or promoting interaction with other proteins (Woodcock et aL, 2003).
14-3-3s exist as dimers with a monomeric molecular mass of 30 kilodaltons. Each 
monomer in the U-shaped dimer is composed of nine anti-parallel a-helices (van 
Hemert et a l, 2001), and can bind one target molecule, predominantly tlnough 
phosphorylated serine residues in the target substrate (Fu et a l, 2000) [Figure 
1.3B(i)].
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This U-shape creates a negatively charged groove containing highly conserved 
amino acids between each isofonn and more variable residues on the outside of the 
molecule. The N-tenninus of 14-3-3 is involved in dimer formation [Figure 
I.3B(ii)] (Liu et al, 1995; Xiao et a l, 1995) with the dimer interface formed by the 
interaction of helix a l  from one monomer (residues 5-21) with helixes a3 and a4 
from the other monomer (residues 58-89).
The sides of the channel are foimed by the C-teiminal domains (van Hemert et a l , 
2001). Until recently it was thought that all 14-3-3 isofomis contained a nuclear 
export (NES) within this region and that this was responsible for the localisation of 
target ligands to the cytoplasm. However, recent work by Brunet et a l  (2002) has 
now shown that this region is in fact required for ligand binding and does not act as 
an NES. By mutating lysine-49, which plays an essential role in ligand binding, the 
group were able to show that this 14-3-3 mutant, that could not now bind any of its 
ligands, homed to the nucleus. If the C-tenninal domain did contain an NES then 
14-3-3 would localise to the cytoplasm in this case. It seems now that 14-3-3 
proteins influence the sub-cellular localisation of some of their targets by a process 
of molecular interference. By binding and masking either an NLS or an NES within 
the target, 14-3-3 is thought to be able to prevent these signals from complexing 
with either the nuclear import or export machinery. In this way 14-3-3 is thought to 
facilitate either nuclear or cytoplasmic localisation.
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By binding two ligands simultaneously 14-3-3s are also able to promote a more 
stable interaction with weak interacting motifs or to bring together two different 
proteins that modulate each other’s activity (Fu et al., 2000).
Phosphopeptide library screening for potential consensus sites for 14-3-3 binding 
revealed two motifs: RSXpSXP and RX(Y/F)XpSXP (Yaffe et a l,  1997) where X 
is any amino acid and pS denotes phosphorylated serine. However 14-3-3s have 
also been shown to bind non-phosphorylated substrates such as 5-phosphatase, 
exoenzyme S, A20 and the platelet glycoprotein IB-IX-V complex (Masters et al., 
1999; Vincenz and Dixit, 1996; Du et al., 1996; Campbell et a l, 1997).
1.3.2: 14-3-3S and Cell Cycle Control
Numerous studies have now shown 14-3-3 to play a pivotal role in control of the 
cell cycle. The phosphatase cdc25 is crucial in allowing onset of mitosis. Human 
cdc25C can dephosphorylate tyiosine-15 on the protein kinase cdc2, resulting in 
active cdc2 (Peng et a l, 1997). Cdc2 is part of the cdc2/cycB complex that causes 
G2/M progression. Cdc25C is phosphorylated at serine-216 during interphase 
(Peng et a l, 1997) which creates a 14-3-3 binding site, leading to the sequestration 
of cdc25C in the cytoplasm [Figure 1.3C(i)]. Several kinases that phosphorylate 
serine-216 have been described including C-TAKl (Peng et a l, 1998), Clikl 
(Blasina et a l, 1999) and Cdsl/Chk2 (Blasina et a l, 1999). Substitution of serine- 
216 with alanine leads to abolition of the association. 14-3-3 does not alter the
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catalytic state of cdc25 (Conklin et a l, 1995; Peng et a l, 1997) and this suggests 
that 14-3-3 negatively regulates cdc25C by altering its sub-cellular localisation.
Indeed, cdc25C contains an NLS (Ogg et al, 1994) located near serine-216 (Peng 
et al., 1997). This suggests that 14-3-3 binding can regulate the sub-cellular 
localisation of cdc25C, perhaps by disrupting this signal. Indeed, 14-3-3 has been 
shown to tether Xenopus cdc25C in the cytoplasm by blocking the interaction 
between the NLS in cdc25C and the impoitin a/p  complex (Zeng and Piwnica- 
Worms, 1999; Kumagai and Dunphy, 1999).
However, recent studies by Graves et al. (2001) have shown that 14-3-3 binding is 
not required for the nuclear export of cdc25C. A mutant of cdc25C that could not 
bind to 14-3-3 was seen to accumulate in the nucleus when the cells were treated 
with leptomycin B, which blocks nuclear export. This allowed the conclusion that 
this mutant was still able to enter and exit the nucleus and therefore the complete 
nuclear export of cdc25C required both an intact 14-3-3 binding site and the 
intrinsic NES within cdc25C which is located close to serine-216. Interestingly, 
Lopez-Girona et al. (1999) showed that elimination of a 14-3-3 homologue, 
rad24^, in Schizosaccharomyces pombe causes the nuclear accimiulation of cdc25 
whilst work by Dalai et al. (1999) showed that the cytoplasmic localisation of 
human cdc25C required an intact 14-3-3 binding site.
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As well as being involved in preventing G2/M progression, 14-3-3 can block S- 
phase entry by associating with cdk2 (Laronga et al., 2000). Cdk2 is active when 
coinplexed with the cyclin proteins, which then leads to the phosphorylation of Rb 
family members. This causes cell cycle progression since Rb is no longer able to 
negatively regulate E2F activity. By blocking cdk2 activity 14-3-3a can prevent a 
Gl-to-S transition.
Recent work by Grozinger and Sclireiber, (2000), showed that 14-3-3s could also 
indirectly regulate the activity of both HDAC4 and HD AC 5. The HDACs are 
nuclear proteins involved in repression of transcription. It was found that HDAC4 
and -5  were phosphorylated, which resulted in 14-3-3 binding. This binding caused 
the cytoplasmic localisation of the HD AC molecules, which prevented them from 
contributing to gene silencing. As in the case with cdc25C, 14-3-3 binding was 
found to prevent the association of an NLS within HDAC4 with the iniportin a/p 
heterodimer (Grozinger and Sclmeiber, 2000).
1.3.3: 14-3-3S and DNA Damage Response
DNA damage induces cell cycle arrest providing time for DNA repair before cells 
continue cycling (van Hemert et al., 2001). DNA damage induces the activation of 
both Chkl and Clik2 (Chehab et a l, 2000) which leads to the phosphorylation of 
serine-216 on cdc25C. As described above this creates a 14-3-3 binding site on 
cdc25C leading to nuclear export of this complex, whieh prevents mitotic onset. 14-
5 5
3-3^ has recently been shown to associate with cdc25C in irradiated cells, resulting 
in G2 checkpoint activation (Qi and Martinez, 2003).
The direct target of cdc25C is cdc2, which binds to cyclin B to form the MPF 
(Maturation Promoting Complex). 14-3-3 can also regulate the sub-cellular 
localisation of cdc2 after DNA damage. After damage the activity of cdc2 is 
suppressed through phosphorylation by the Weel and Myt/Mikl kinases (van 
Hemert et a l, 2001). In response to cellular stresses p53 upregulates 14-3-3<j 
(Hermeking et a l, 1997) which then binds the phosphorylated cdc2 and localises it 
to the cytoplasm thus preventing mitotic onset (Chan et a l, 1999). Recent work by 
Bulavin et a l  (2003) has now shown that phosphorylation of serine-214 in cdc25C 
prevents phosphorylation of serine-216 during mitosis. Activation of the IR- 
induced DNA damage checkpoint in mitotic cells did not induce serine-216 
phosphorylation. These findings suggest that mitotic cells lose their ability to 
phosphorylate cdc25C on serine-216 and inactivate cdc2 after DNA damage due to 
the phosphorylation of serine-214 in cdc25C.
Waterman et a l (1998) have now shown that p53 itself is regulated by 14-3-3a 
[Figure 1.3C(ii)]. Noi*mally p53 is phosphorylated at serines-376 and 378. After 
DNA damage serine-376 is dephosphorylated thereby creating a 14-3-3 binding site 
at serine-378. 14-3-3cr then associates with p53 causing an enhancement of p53 
DNA binding activity. As was described above this then leads to up-regulation of 
14-3-3(7 and subsequent cell cycle anest.
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14-3-3 proteins can also regulate both Chkl and W eel. The S. pombe 14-3-3 
homologues, Rad24 and Rad25 bind to Clilcl in response to DNA damage (Chen et 
al., 1999). Although the nature of this association is unknown it may target Clikl to 
either a specific part of the cell or target protein. Recent findings by Honda et al. 
1997) now point to both 14-3-3(3 and 14-3-3<  ^ being able to bind to Weel. 
Phosphorylation of W eel creates a 14-3-3 binding site on the molecule and work 
by Wang et al. (2000) showed that this association causes an increase in Weel 
stability and kinase activity. This causes an increase in the G2/M cell population.
1.3.4: 14-3-3s and Apoptosis
Apoptosis is the process of programmed cell death that plays a crucial role in the 
nonnal development of tissues as well as in the pathophysiology of a variety of 
diseases including cancer (Fu et a l, 2000). 14-3-3s play a pivotal role in control of 
apoptosis. The Bcl-2 family of pro- and anti-apoptotic molecules are involved in 
the cell death response. As described above, the family consist of Bcl-xs, Bad, Bak 
and Bax that stimulate apoptosis and Bcl-2, MCL-1 and Bcl-x^ that inliibit the 
process (van Hemert., 2001). Both Bcl-2 and Bc1-xl are bound, and inactivated, by 
Bad (Yang et a l, 1995; Mok et a l, 1999) which leads to cell death.
However, 14-3-3 proteins can bind Bad, which prevents it from interfering with the 
function of both Bcl-2 and Bc1-xl (Xing et a l, 2000) [Figure 1.3C(iii)]. 
Phosphorylation of Bad on serine-136 by Alctl (Datta et a l,  1997) and on serines-
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112 and 155 by RSKl (Tan et a l, 2000) and PKA (Lizcano et a l, 2000), in 
response to sui'vival signals, creates three 14-3-3 binding sites within the molecule. 
14-3-3 then sequesters Bad in the cytoplasm, away from the mitochondrial bound 
Bcl-2 and Bc1-xl. Dephosphorylation of Bad by the calcium activated protein 
phosphatase, calcineurin, allows Bad to associate with its targets which leads to 
caspase release from the mitochondria and subsequent cell death.
The activation of transcription factors is an important process in maintaining the 
balance between agonists and antagonists of apoptosis (Rosenquist, 2003). The 
Forkhead Transcription Factor 1 (FKHRLl) is involved in transcribing apoptosis- 
promoting genes (Rosenquist, 2003). It is regulated by Alctl kinase, which is 
involved in promoting cell survival. Activated Alctl translocates to the nucleus 
where it phosphorylates FKHRLl (Brunet et a l, 1999). This allows 14-3-3 to bind 
FKHRLl and to retain it in the cytoplasm. Dephosphorylation of FKHRLl due to 
removal of survival signals leads to dissociation of 14-3-3 from FKHRLl and 
translocation of the molecule to the nucleus where it can induce apoptosis.
ASKl (Apoptosis Signal-Regulating Kinase 1) is stimulated by pro-apoptotic 
elements such as TNFa and cisplatin. When ASKl becomes phosphorylated, 14-3- 
3 can bind and inhibit the pro-apoptotic effects of ASKl (Zhang et a l, 1999). An 
ASKl mutant that has an abrogated ability to bind 14-3-3 has an entranced pro- 
apoptotic effect (Zhang et a l, 1999).
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1.3.5: Regulation of the 14-3-3s
Possible mechanisms that regulate the activities of the 14-3-3s include isofonn 
specificity and post-translational modifications such as phosphorylation (Fu et a l, 
2000). The various isoforms of 14-3-3 all contain the same key residues involved in 
ligand binding (Yaffe et a l, 1997; Rittinger et a l, 1999). This would suggest that 
isoform specificity is not important in the activity of these molecules and work by 
Muslin et a l (1996) showed that different 14-3-3 isoforms could bind peptides with 
similar affinities. Some 14-3-3s do have specificity to target ligands. 14-3-3r| is the 
only member of the family that can bind the zinc finger protein A20 (Vincenz et a l, 
1996).
Post-translational modifications may regulate activity. 14-3-3^ is phosphorylated 
on serine-185, which lies within a proline-directed kinase consensus. This 
phosphorylation gives rise to the 5 isoform (Aitken et a l, 1995). Work by Liu et a l 
(1995) showed that this site is near the N-terminus of helix 8, close to the ligand- 
binding groove, suggesting that it may play a role in ligand binding. Work by 
Dubois et a l  (1997) also showed that 14-3-3^ was phosphorylated on tlneonine- 
233 by Casein Kinase I. This negatively regulates the binding to c-Raf, presumably 
since this site is close to residues involved in ligand binding. Interestingly, recent 
work by Woodcock et a l  (2003) has shown that phosphorylation of serine-58 in 
14-3-3Ç by a sphingosine-dependent kinase (SDK) led to the disruption of the 
dimeric status of 14-3-3^ since serine-58 is located near to the dimer interface. 
Monomeric \A-3-3C, could still bind to a phospho-peptide target. Indeed, recent
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findings by Hamaguchi et al. (2003) have now shown that this SDK is in fact 
identical to the C-terminal half kinase domain of PKCô. Cleavage of PKC5 by 
caspase-3 releases the kinase domain which then confers SDKl activity, leading to 
phosphorylation of 14-3-3(^ on serine-58 (Hamaguchi et al., 2003). These findings 
could have profound implications for the understanding of the ways that 14-3-3s 
regulate their targets in vivo.
1.3.6: 14-3-3 and Cancer
Given that a significant number of 14-3-3 ligands are proto-oncogenes or oncogenic 
products this suggests that 14-3-3s may be involved in neoplastic transformation 
(Fu et a l, 2000).
Recent work by Craparo et al. (1997) showed that 14-3-3 interacts with the insulin­
like gi'owth factor-1 receptor (IGFIR). The binding site within IGFIR is near a 
quartet of serines that are essential for cell transfomiation mediated by IGFIR. This 
would suggest that 14-3-3 proteins are involved in tumorogenesis in this case. 
Indeed, in many major types of lung cancer, both IGFIR and 14-3-3 proteins have 
elevated levels (Fu et a l, 2000). In contrast, work by McDonald et al. (1994) 
showed that 14-3-3s, located on chromosome 17, was in a region frequently 
mutated in several cancers. This suggests that this isoform, and perhaps others, are 
important in the suppression of neoplastic transformation.
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Figure 1.3A: 14-3-3 Binding Ligands
Tabular representation of a range of 14-3-3 binding ligands showing the recognition 
sequence within the ligand and the effect of 14-3-3 binding. The figure is adapted 
horn Aitken. (2002), Table 1.
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LIGAND BINDING SEOUENCE(S) EFFECT OF 14-3-3 BINDING
cdc25C RSPpS(216)M P Cytoplasmic retention/Block Mitosis
cdc25A RSPpS(290)M P Prevent binding to cyclinBl/Block Mitosis
Bad RHSpS(112)YP, Cytoplasmic retention/inhibit
RSRpS(136)AP pro-apoptotic effect
FKHRLl RSCpT(32)W P, Cytoplasmic retention/inhibit
RAVpS(253)MD pro-apoptotic effect
ASKl RSIpS(967)LP Inhibit pro-apoptotic effect
p53 KG OSTpS(378)RH Enhance DNA binding
Middle T Antigen RSHpS(257)YP Cause neoplastic transformation in some tissues
RAF-1 RSTpS(259)TP,
RSApS(62I)EP
Maintain both inactive and active states
SLOB R SNpS(54)Al, Modulate voltage sensitivity of associated slowpoke
RSApS(79)SE potassium channels
CBL RHpS(619)LPFpS(623)
RLGpS(639)TFpS1642)
Unknown
cdk2 GVTpS(229)MP,
YKPpS(236)FP
Cytoplasmic retention/Cause Gl/S block
HDAC4 RKTApS(246)EP
RTQpS(467)AP
R AO pS(632)SP
Cytoplasmic retcntion/Prevent cell cycle progression
HDAC5 RKTApS(259)W P
RTOpSf498)SP
Cytoplasmic rctention/Prevent cell cycle progression
5-Fhosphatase L V L R SE SE E K V V (371) Stimulate phosphatase activity
Exoenzyrae-S DALDL(428) Stimulate ADP-ribosylation activity
Figure 1.3B: Diagram of 14-3-3
i. Diagrammatical representation of the 14-3-3 binding cleft. This U-shaped 
binding region consists of highly conserved amino acids, which forms an 
amphipathic groove. Each monomer can bind one target molecule (as shown 
by representation by the synthetic peptides).
ii. Diagranunatical representation of the N-terminal interaction of the 14-3-3 
dimer. The dimer is formed by the interaction of helix a l  from one 
monomer with helixes a3 and a4 from the other monomer.
i and ii: The representations were adapted from the structure of 14-3-3<  ^bound to 
R18 peptide (Protein Data Bank accession number 1A38) (Petosa et al., 1998).
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Figure 1.3C: Effects of 14-3-3 Binding on Different Ligands
i. 14-3-3 sequesters cdc25C in the cytoplasm. C-TAK and both Chkl and
Chk2  can phosphorylate cdc25C, allowing 14-3-3 to form a complex with 
and sequester cdc25C in the cytoplasm. This creates a G2/M block.
ii. 14-3-3 can increase the DNA binding affinity of p53. After DNA damage
p53 becomes dephosphorylated at serine-376 which creates a 14-3-3 
binding site at serine-378. This results in an enhancement of the ability of 
p53 to bind to DNA.
hi. 14-3-3 can block Bad induced cell death. Following survival signals, Bad
becomes phosphorylated by Aktl, RSKl and PKA. This allows 14-3-3 to 
bind and sequester Bad away from its target substrates in the mitochondria. 
This promotes cell survival. Blue lines indicate stimulatory effect; red lines 
indicate inliibitory effect.
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C- T A K /C H K I/ C H K 2
NUCLEUS
G2/M Block
CYTOPLASM
NUCLEUS
Increase in DNA 
binding affinity o f p53
CYTOPLASM
SURVIVAL SIGNALS
iii)
MITOCHONDRIA Bcl-xl Pro-apoptotic 
function of Bad is 
blocked
1.4: Objectives
Recent work in the laboratory has shown that 14-3-3 can influence E2F, via the 
DP3 sub-unit (Cruickshank, 2000). This interaction is dependent on the basic 
portion of the bi-partite NLS of DP3. Removal of this region results in a loss of 14- 
3-3 binding as well as an accumulation of the E2F/DP3 complex in the cytoplasm. 
Since 14-3-3s are loiown to be able to influence the sub-cellular localisation of 
certain target substrates this result raised the question of whether 14-3-3 was 
influencing the sub-cellular localisation of the E2F/DP3 heterodimer.
This project firstly attempted to answer whether 14-3-3 was influencing the ability 
of E2F/DP3 to accumulate in the nucleus. To answer this question, a mutant of DP3 
was generated that failed to bind 14-3-3 but still retained the ability to localise to 
the nucleus. The generation of this mutant therefore showed that 14-3-3 was not 
influencing the nuclear accumulation of DP3.
The ability of E2F to fra/i.s'-activate its target genes is dependent on its nuclear 
accumulation. It was therefore important to generate this DP3 mutant, that was able 
to localise to the nucleus, fonn a complex with E2F and yet be defective in its 
ability to bind 14-3-3. This would then allow the further elucidation of the role of 
14-3-3 over E2F activity, via DP3.
The project then analysed whether 14-3-3 could influence the cell cycle, via E2F. 
Both E2F and 14-3-3 have key roles to play in the control of cell cycle progi'ession.
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It was postulated that 14-3-3 may influence the cell cycle, via E2F, as it has been 
shown to do for a wide array of target substrates. Subsequent analysis revealed a 
role for 14-3-3 in the control of the cell cycle, specifically S-phase entry. This was 
dependent on the ability of 14-3-3 to bind to DP3.
14-3-3S have been shown to play a pivotal role in the control of apoptosis. Recent 
work has now pointed to a role for E2F in the apoptotic response. Given this, it was 
of interest to analyse whether 14-3-3 could influence E2F-mediated apoptosis. 
Further investigation revealed a role for 14-3-3 in the control of E2F-mediated 
apoptosis. Again, this was dependent on the ability of 14-3-3 to bind DP3.
Finally, further analysis revealed a role for DNA damage in the interaction between 
DP3 and 14-3-3. DNA damage caused an abrogation in binding between 14-3-3 and 
DP3. Given that 14-3-3 is intricately involved in checkpoint control, this result may 
point to a role for the DP3/14-3-3 interaction in a similar checkpoint control 
mechanism.
This study has now shown that an intricate relationship exists between E2F and 14- 
3-3 and that this relationship is dependent on the DP3 portion of the E2F/DP 
heterodimer. These results now point to a role for 14-3-3 in the control of E2F- 
mediated cell cycle progi'ession, apoptosis and DNA damage response.
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Chapter 2: Materials and Methods
2.1: PLASMIDS
The following plasmids have previously been described; pCMV-HA-E2F5 and 
pCMV-TAD-HA-E2F5 (Allen et a l, 1997), pG-DP30 (de la Luna et a l, 1996), 
pCE-luc (Botz et a l, 1996) and pSG5 (Green et a l, 1988). The vector pAS-RFP 
was kindly supplied by the Milligan laboratory and was purchased from 
CLONTECH Laboratories (cat no. K6100-1).
Both pCMV-14-3-3s-myc encoding mammalian expression myc-tagged 14-3-3s 
and pGEX-14-3-38  encoding bacterial expression GST-14-3-3s were kind gifts 
from Prof. A. Aitken.
Both pGEX-DP3 and pGEX-DP3 5S encoding bacterial expression GST-DP3 and 
GST-DP3 5S were constructed by amplifying DP3 wt and DP3 5S by PCR from 
the mammalian expression plasmids pG-DP3 and pG-DP3 5S respectively using 
the following oligonucleotides containing the indicated restriction enzyme sites.
Smal (5'-3'): TACCCGGGAATGGTCACTCAGACTC 
Xhol (3'-5'): GGGAGGAGGGGTCTTATTGAGCTCAT
PCR amplification was earned out using Taq polymerase (Promega). PCR was 
carried out using the manufacturers incubation buffer for 30 cycles as follows: 5 
minutes dénaturation at 94°C, followed by 30 cycles of dénaturation at 94°C for
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30 seconds; annealing at 51°C for 30 seconds; extension at 72°C for 1 minute (last 
cycle 5 minutes). These fragments were then sub-cloned into the pGEX backbone 
vector by digesting the backbone and the fragments with the indicated restriction 
enzymes and using DNA ligase to glue the fragments into the pGEX vector. The 
products were sequenced in the 5' to 3' direction using the following sequencing 
oligonucleotides to ensure that no random mutations had been introduced during 
the PCR process; oligol: 5'-GCTGGCAAGCCACGTTTGGTGGTGGCGACC-3' 
and oligo2: 5'-CCATTCAGCTGCCATTTATAATC-3'. The sequencing process 
was carried out by MWG-Biotech Ltd. The oligos were amanged as follows:
 ^ oligo2 sequenceoligol sequence   _ _ _ _ _ _ _ _
START --------------------------------------------------------------------------------------------  FINISHDP3 DNA
2.2: ANTIBODIES
Primary Antibodies were as fallows'.
14-3-3s Rabbit polyclonal T16 (Santa Cruz) (Blocking peptide was T16P)
DP2 Mouse monoclonal G12 (Santa Cruz)
DP3 (7.2) Rabbit polyclonal raised against the N-temiinal sequence in DP3
coded b y : E V A L A T G Q L P A S N S H Q ( d e l a  Luna et a l,
1996)
HA Mouse monoclonal HAl 1 (Babco)
myc Mouse monoclonal 9E10 (Santa Cmz)
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Secondary Antibodies were as follows:
Aiiti-Ig-AP Alkaline phosphatase conjugated (Promega)
Anti-Ig-HRP Horseradish peroxidase conjugated (Amersham)
Anti-Ig-Alexa Fluor 488 Fluorescein conjugated (Molecular Probes)
Anti-Ig-Alexa Fluor 594 Fluorescein conjugated (Molecular Probes)
Anti-CD20"FITC Fluorescein conjugated (Becton Dickinson)
2.3; SITE-DIRECTED MUTAGENESIS
In vitro mutagenesis was earned out using the QuikChange Single Site-Directed 
Mutagenesis Kit (Stratagene). To obtain the 2S, 3S, 4S and 5S mutants it was 
necessary to create multiple rounds of individual mutations using wild type DP3Ô 
as the initial template and the new mutant as the template thereafter. This was 
done by the use of the following oligonucleotide primers (Sigma-Genosys) which 
carried the relevant mutation in one or more bases which thereby created a 
product which carried the relevant serine to alanine change:
1.DP3 2S (S56A/S58A):
(5'-3'): GACTCTGATTTTGCAGAAGCTAAACGAAGCAAAAAAGGAG 
(3'-5'): CTGAGACTAAAACGTCTTCGATTTGCTTCGTTTTTTCCTC
2. DP3 3S(S61A):
(5'-3'): GACTCTGATTTTGCAGAAGCTAAACGAGCCAAAAAAGGAG 
(3'-5'): CTGAGACTAAAACGTCTTCGATTTGCTCGGTTTTTTCCTC
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3. DPS 4S (S53A):
(5'-3'): GCTAGAGAATTTATAGACGCTGATTTTGCAGAAGC 
(3'-5'): CGATCTCTTAAATATCTGCGACTAAAACGTCTTCG
4. DP3 5S (S42A):
(5'-3'): GCTGCTGGCTGGGTTCCCGCTGATAGAAAACG 
(3'-5'): CGACGACCGACCCAAGGGCGACTATCTTTTGC
After each round of mutations was complete the product was sequenced in the 5' 
to 3' direction using both the T7 promoter to create a sequencing oligonucleotide 
and the following oligonucleotide: 5'-CCATTCAGCTGCCATTTATAATC-3' 
which was located further downstream. This process was carried out by MWG- 
Biotech Ltd. Tlrroughout the work presented in this thesis DP3 corresponds to 
DP36 since the DP3 constmcts made above were constructed from the 
mammalian expression vector containing the full length coding sequence of DP3Ô 
(de la Luna et a l, 1996).
2.4: TRANSFECTION
Cells were maintained in Dulbeccos Modified Eagle Medium (DMEM) (Gibco 
BRL), supplemented with 10% (v/v) Foetal Calf Serum (FCS) and antibiotics 
(lOmg/ml streptomycin and lOOU/ml penicillin) (Gibco BRL) at 37”C in a 5% 
CO2 /H2 O atmosphere. All cell culture and transfection work was carried out in a 
class II microbiological safety cabinet.
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Ai'ound 24 hours before transfection the cells were gently removed from the 
storage flasks by addition of trypsin-EDTA (Gibco). Trypsinisation was stopped 
by the addition of DMEM. Cells were then plated out at a concentration of 1x10^ 
per 6 -well plate (p6 ), 2x10^ per 6 cm plate (p60), 5x10^ per 10cm plate (p i00) and 
2x10^ per 15cm plate (p i50). Final DNA concentrations were made up with pSG5 
or pcDNA3 empty vectors, with final volumes of DNA for each size of plate as 
follows: (six well plate: 8 pg), (p60: 15pg), (p i00: 30pg) and (pl50: 90pg).
For all assays the cells were transfected using the calcium phosphate-DNA 
precipitate method. Based on a 15cm plate (p i50), 1.35ml of distilled water was 
added to 90pg of total DNA. 150pl of 2.5M CaCfr was then added to the 
DNA/water mix and then this was then added drop-wise to 1.5ml of 2X Hep es 
Buffered Saline (HBS) to give a final volume of 3ml. This mix was then vortexed 
briefly and then left at room temperature for 30 minutes, during which time the 
cells were washed twice in sterile PBS and fi'esh media was added.
After 30 minutes the transfection mix was vortexed briefly again and was then 
added drop-wise to the cells. The cells were then returned to the incubators. 
Around 17-20 hours post-transfection the cells were washed tliree times in sterile 
PBS to remove the precipitate that had formed, 30ml of fresh DMEM containing 
serum and antibiotics was added and the cells were returned to the incubators to 
allow appropriate gene expression of the transfected plasmids. After a further 48 
hours the cells were haiwested for the appropriate assays. Transfections for other
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sizes of plates (six well plate, p60 and p i 0 0 ) involved scaling of the reagents in 
the appropriate manner.
2.5: PURIFICATION OF RECOMBINANT GST PROTEINS
Transformed BL21s were grown overnight in a 37°C shaker in a 50ml culture. 
This culture was diluted in a further 450ml until bacteria had reached mid- 
logarithmic stage. Protein expression was induced by the addition of 0.5mM (final 
concentration) of IPTG (isopropyl-p-D-thiogalactopyi'anoside) (Melford 
Laboratories Ltd) and bacteria were incubated in 37°C shaker for 3 hours. 
Bacterial pellet was lysed in 10ml PBS with protease inhibitors then sonicated 
tliree times for 10 seconds at 4°C. Triton X-100 was then added (1% v/v) and the 
bacteria were left on a roller at 4°C for 30 minutes. Cells were centrifuged at 
13000 rpm for 30 minutes and supernatant was removed.
300pi of glutathione-agarose beads (33% v/v) in suspension (0.05% NaNa in PBS) 
was washed in PBS (3 x 5 minutes) and the bacterial supernatant was added to the 
beads, which were placed on a roller at 4°C for 1 hour. The beads were washed 
twice with 20ml of PBS/Triton X-100 (1% v/v) then tlii'ee times in 20ml PBS 
alone after which they were transferred to a 1.5ml eppendorf, and resuspended in 
GST storage buffer (PBS/PMSF (ImM final concentration)/Glycerol (10% v/v). 
Protein expression was measured by coomassie after SDS-PAGE.
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2.6: IMMUNOPRECIPITATION
COS-7 cells were plated out onto p i 50 plates at a concentration of 2x10^ per plate. 
Ai'ound 65 hours post-transfection the media was removed and the cells were 
washed twice in non-sterile PBS. The cells were tiypsinised and the trypsinisation 
was stopped by the addition of complete DMEM, after which the cells were 
transferred to 50ml falcon tubes and pelleted in a Sorvall centrifuge for 5 minutes 
at 1000 rpm. The media was removed and the cells were washed in PBS, 
transferred to a 1.5ml eppendorf and pelleted once more for 15 minutes at 13000 
ipm at 4°C.
The supernatant was removed and the cells were resuspended in 1ml of micro­
extraction (ME) buffer (20mM HEPES, lOOmM NaCl, 25% Glycerol, 50mM 
NaF, 0.2mM EDTA, 0.5mM PMSF, 60mM p-Glycero-phosphate, ImM Na3 V 0 4 , 
0.1% NP-40 and protease inliibitor cocktail) and left on ice for 30 minutes. Cells 
were then centrifuged for 15 minutes at 13000 rpm, the supernatant was removed 
and the appropriate P-Galactosidase (p-Gal) and protein concentration assays 
were carried out where necessary. The cell extract was pre-cleared for 20 minutes 
on a rotating wheel at 4°C by adding the extract to 50pl of protein-G beads 
(Sigma) which had previously been equilibrated by washing in ME buffer.
The beads were centrifuged for 3 minutes at 4500 rpm at 4°C and the pre-cleared 
cell extract was removed to a clean 1.5ml eppendorf. After this, 5% of the extract 
was removed for input and the rest of the extract was added to the 
immunoprecipitating antibody, which had previously been coupled to protein-A
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beads (Sigma). This was achieved by equilibrating SOql of protein-A in ME buffer 
then adding 5pTs of the immunoprécipitation antibody to the beads in a total 
volume of 500pl of ME buffer. The beads and antibody were placed on a rotating 
wheel at 4°C for 5 hours to allow efficient binding.
Once the cell extract had been added to the protein-A/antibody complex, the 
samples were placed on a rotating wheel at 4°C overnight. The samples were 
washed thi'ee times in 1ml of ME buffer, the supernatant was removed and 
loading buffer was added to the beads. The samples were boiled for 3 minutes to 
dissociate the antigen/antibody complex from the beads then the samples were 
loaded onto an SDS-polyacrylamide gel, the proteins were blotted onto 
nitrocellulose membrane (Inverclyde Biologicals Ltd) then detected using the 
appropriate antibodies.
For immunoprécipitation of 14-3-3 and DP2 from ML-1 cells protocol was 
repeated as above except 1 0 x 1 0  ^ cells were collected and lysed in 
immunoprécipitation buffer. Immunoprécipitation from cells treated with 
etoposide (Sigma) was as above except a final concentration of lOpM etoposide 
was added to the cells 15 houis before harvesting. Immunoprécipitation assays 
were carried out three times unless otherwise stated.
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2.7: IN  VITRO PROTEIN EXPRESSION
In vitro transcription and translation of cDNA plasmids was carried out using the 
TNT T7 coupled reticulocyte lysate system from Promega. The protocol was 
carried out as per the manufacturer guidelines, in the presence and absence of 
methionine. To ensure expression, 10% of the extract was used in SDS-PAGE and 
then subjected to autoradiography overnight.
2.8: IN  VITRO PULL-DOWN ASSAY
The cold in vitro translated product was firstly pre-cleared overnight. An 
equivalent bed volume of glutathione-agarose beads, which had been washed 
twice in LDB pull-down buffer (20mM HEPES, lOOmM KCl, 12mM MgCfr, 
2mM EDTA, 17% Glycerol, 0.2mM NaF, 0.5mM PMSF, 60mM |3-Glycero- 
phosphate, ImM Na3 V 0 4  and protease inliibitor cocktail), was added to the 
amount of in vitro translated product to be used in the assay. The in vitro 
translated product was pre-cleared in 0.5ml LDB buffer overnight on the rotating 
wheel at 4°C.
The beads were centrifuged at 4500 rpm for 2 minutes at 4°C and the pre-cleared 
supernatant was removed to a fresh 1.5ml eppendorf. The appropriate amount of 
GST (used as a negative control) and GST-fusion protein, bound to glutathione- 
agarose beads, was washed twice in LDB buffer and the pre-cleared extract was 
added to the beads for 1 hour on the rotating wheel at 4°C. The beads were 
washed 6  times in LDB buffer, SDS-sample buffer was added and the samples
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were boiled for 5 minutes, electroplioresed and then subjected to SDS-PAGE 
electrophoreses and western blotting. In vitro pull-down assays were carried out 
tliree times unless othei*wise stated.
2.9: PULL-DOWN FROM CELL EXTRACTS
For pull-downs from cell extracts, COS-7 cells were seeded out onto p i 50 plates 
at a concentration of 2x10^ per plate. Ai’ound 65 hours post-transfection the cells 
were removed from the plates by trypsinisation. Complete media was then added 
and the cells were transferred to 50ml falcon tubes and centrifuged at 1000 rpm 
for 5 minutes. The media was removed and the cells were washed in PBS, 
transferred to 1.5ml eppendorfs and centrifuged at 13000 rpm for 20 minutes at 
4°C.
The supernatant was removed and the cells were resuspended in 1ml of micro- 
extraction buffer (ME) buffer (20mM HEPES, lOOmM NaCl, 25% Glycerol, 
50mM NaF, 0.2mM EDTA, 0.5mM PMSF, 60mM p-Glycero-phosphate, ImM 
Na3 V 0 4 , 0.1% NP-40 and protease inhibitor cocktail). After lysing on ice for 30 
minutes the cells were centrifuged at 13000 ipm for 20 minutes at 4°C. The 
supernatant was removed and the appropriate (3-Galactosidase (p-Gal) and protein 
concentration assays were then carried out.
GST or the appropriate GST-fusion proteins coupled to glutathione-agarose beads 
were washed twice in ME buffer to allow equilibration with the cell extract.
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Al'ound Img of cell extract was added to the beads and the samples were placed 
on the rotator wheel at 4°C for 3 hours. The beads were washed tluee times in 1ml 
of ME buffer. SDS loading buffer was added to the samples, which were then 
subjected to SDS-PAGE electrophoreses and western blotting. Pull-down assays 
from cells were earned out tlu'ee times unless otherwise stated.
2.10: IMMUNOFLUORESCENCE
COS-7 cells were plated out onto glass coverslips in six-well plates at a 
concentration of 1x10^ per plate. Around 65 hours post-transfection the cells were 
fixed onto coverslips using 4% (w/v) paraformaldehyde (Sigma). The cells were 
then permeabilised using 1ml of 1% (v/v) Triton X-100 (Sigma).
After 15 minutes the cells were blocked in 10% (v/v) FCS in PBS. The 
appropriate primary antibodies, diluted to 1 in 500 in 1% FCS (v/v) in PBS, were 
added to the coverslips and left at room temperature for 30 minutes. The primary 
antibodies were removed and the cells were subjected to 3x10 minute washes in 
PBS with 10% (v/v) FCS, followed by a 1x10 minute wash in PBS alone.
The coverslips were incubated for 30 minutes in the appropriate secondary 
antibodies; Alexa Fluor 488 goat anti-mouse or Alexa Fluor 594 goat anti-rabbit 
IgG conjugated to fluorescein succinimidyl (Molecular Probes), diluted to 1 in 
400 in 10% FCS (v/v) in PBS. The secondary antibodies were removed and the 
cells were given 5x10 minute washes in PBS alone.
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To allow detection of the cells on the coverslips the cell nuclei were stained with a 
final concentration of 5juM of DAPI (4’,6-Diamidino-2-phenylindole 
dihydrochloride). The coverslips were dried and finally mounted onto glass slides 
using citifluor (Citifluor Ltd) before being viewed using a fluorescence 
microscope (Olympus).
2.11: LEPTOMYCIN-B TREATMENT
This assay was earned out as per the immunofluorescence protocol except that, 16 
hours before harvesting the cells, leptomycin-B (Novartis) was added to a final 
concentration of 1 pM.
2.12: FLUORESCENCE ACTIVATED CELL SORTING (FACS)
For FACS analysis, COS-7 cells were plated out onto p i 00 plates at a 
concentration of 5x10^ per plate. Around 65 hours post-transfection the cells were 
dissociated from the dishes using 1ml of cell dissociation buffer (Sigma).
The cells were scraped on ice into polypropylene tubes, centrifuged at 1000 rpm 
for 3 minutes, the supernatant was removed and the cells were washed in PBS. 
200pl of DMEM containing 20pl of anti-CD20 antibody leu-16 (Becton 
Dickinson) coupled to fluorescein isothiocyanate (FITC) was added to the cells. 
The cells were washed again then fixed overnight by the addition, dropwise, of a 
50% ethanol/50% PBS solution.
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The following day the cells were washed then resiispended in 400pl of propidium 
iodide (20pg/ml) and 200pl RNase (125U/ml) in PBS and incubated in the dark, 
on ice for 20 minutes. Flow cytometry was perfoiined using a Becton Dickinson 
fluorescence activated cell sorter. The cell cycle profile of the transfected 
population of cells was detennined by analysing the intensity of the propidium 
iodide staining in cell populations that were positive for FITC staining. At least 
1 0 , 0 0 0  events were counted in each sample.
2.13: LUCIFERASE REPORTER ASSAY
For reporter assays, COS-7 cells were plated out onto p60 plates at a 
concentration of 2x10^ per plate. Around 65 hours post-transfection the cells were 
removed fi'om the dishes using 300pl of reporter lysis buffer (25mM TRIS-H3 PO4  
pH 7.8, 2mM 1,2-diaminocyelohexane tetra-acetic acid, 2mM DTT, 10% glycerol 
and 1% Triton X-100). The cells were collected into 1,5ml eppendorf tubes and 
centrifuged at 13,000 rpm for 2 0  minutes.
The supernatant was removed and 50pFs was taken from each sample and added 
to 50pl of p-Galactosidase substrate buffer (200mM sodium phosphate buffer pH 
7.3, 2mM MgCb, lOOmM |3-mercaptoethanol and 1.33mg/ml 0-nitrophenyl-(3~D- 
galactopyianoside) to determine transfection efficiency. To assay for luciferase 
activity 50pl was removed from each sample and added to an 80 well plate which 
was then placed into a Microlumat Plus luminometer (Berthold Technologies) 
which injected lOOpl of luciferase assay reagent (Promega) into each sample.
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2.14: CELL PROLIFERATION (Brdu) ASSAY
COS-7 cells were seeded out onto coverslips in six-well plates at a concentration 
of 1x10^ per well. Around 65 hours post-transfection lOpM (final concentration) 
Brdu (5-bromo-2'-deoxyuridine) (Roche) was added to the cells in culture and left 
for 1 hour. The cells were washed twice in non-sterile PBS and fixed for 45 
minutes in ethanol (70%) in 50mM glycine buffer, pH 2 .
The coverslips were washed twice in PBS and one coverslip was removed and 
used in an immunofluorescence assay to ensure efficient expression of the 
exogenous protein. The remaining coverslips were simultaneously incubated with 
5U/ml DNAse and the appropriate dilution of anti-Brdu-FLUOS antibody for 1 
hour at 37°C. The coverslips were washed three times in PBS, stained with DAPI 
and mounted onto glass slides using citifiuor. The samples were viewed using a 
fluorescence microscope (Olympus).
2.15: TUNEL ASSAY
COS-7 cells were seeded out onto coverslips in six-well plates at a concentration 
of 1x10^ per well. Around 65 hours post-transfection the cell were fixed onto 
coverslips by the addition of 4% (w/v) parafonnaldehyde for 1 hour. One 
coverslip was removed and used in an immunofluorescence assay to ensure 
expression of the exogenous proteins. The coverslips were washed twice in PBS 
and permeabilised on ice for 2 minutes by the addition of 1% (v/v) Triton X-100 
in PBS. The coverslips were washed again in PBS and the TUNEL (TdT-
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mediated dUTP-X nick end labelling) reaction mixture (50% terminal 
transferase/50% fluorescein-dUTP) was added for 1 hour at 37°C.
The samples were washed twice in PBS and rinsed in DAPI stain to enable 
detection of the cells. The coverslips were mounted on glass slides using citifiuor 
and analysed using a fluorescence microscope.
2.16: CYCLOHEXIMIDE TREATMENT
COS-7 cells were seeded out onto p i 50 plates at a concentration of 2x10*^  per 
plate. After washing off the DNA precipitate, the cells on each p i 50 were 
trypsinised and split into the relevant number of p i 0 0  plates depending on the 
number of time points. This method ensured that transfection efficiency was 
maintained between each time point.
Aiound 48 hours later a final concentration of O.Olpg/pl cycloheximide 
(Promega) was added to the relevant plates and each plate was harvested 
thereafter at the conect time point. The cell extracts were lysed in ME buffer and 
the supernatant was removed after which the samples were subjected to SDS- 
P AGE and finally western blotting.
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2.17: WESTERN BLOTTING
To allow measurement of protein expression in cells the extracts were lysed in 
ME buffer, left on ice for 30 minutes and centrifuged at 13000 ipm for 20 minutes 
at 4°C. The supernatant was removed and protein concentration was measured by 
use of Bradford reagent (Biorad). lOOpg of total protein was loaded onto a SDS 
polyacrylamide gel and the samples were subjected to western blotting onto 
nitrocellulose membrane (Inverclyde Biochemicals Ltd), then blocked in 
PBS/10% (w/v) powdered milk.
The membrane was washed tlmee times for 10 minutes in PBS/0.1 % Tween-20 
(Sigma) and the primary antibody was added overnight. The membrane was 
washed three times in PBS/Tween and the appropriate secondary antibodies were 
added [either alkaline phosphatase-conjugated goat anti-rabbit or anti-mouse IgG 
(1:5000, Promega) for chemi-luminescent detection or horseradish peroxidase- 
conjugated goat anti-rabbit or anti-mouse IgG (1:5000, Amersham) for ECL].
Chapter 3: A nuclear DP3 mutant that cannot bind to
14-3-3
3.1: Introduction
Recent work in this laboratory (Cruickshanlc, 2000) has shown that DP3 interacts 
with the epsilon isoform of 14-3-3 (14-3-38). This interaction is mediated via the 
region containing the bi-partite nuclear localisation signal (NLS) of DP3. 
Furtheiinore it has been shown that this interaction is dependent on the basic 
region of the NLS [Figure 3.1(i) and (ii)]. Removal of this region (creating the 
DP3 AB construct) abrogates the ability of 14-3-3s to bind DP3, and to thereby 
influence E2F function (Cruickshanlc, 2000).
Flowever, despite providing a useful insight into the nature o f the relationship 
between 14-3-3 and the DP3/E2F heterodimer, the DP3 AB mutant has its 
limitations as an effective biochemical tool since it becomes localised to the 
cytoplasm. Given the role that 14-3-3 proteins are known to play in mediating the 
sub-cellular localisation of many of their target substrates, this raised the question 
of whether the cytoplasmic localisation was due to disruption of the NLS or 
whether 14-3-3 plays a role in mediating the nuclear localisation of DP3. The 
cytoplasmic localisation of DP3 AB also complicates the studies aiming to 
understand the role of a nuclear transcription factor complex.
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The work described in this chapter aimed to identify a DP3 mutant that was 
unable to bind 14-3-3 but continued to localise to the nucleus. Such a mutant 
would allow the further elucidation of the nature of the E2F/DP3/14-3-3 
interaction.
3.2: RESULTS
3.2A: Identification of a DP3 mutant that cannot bind
14-3-3 in vitro
In order to identify a mutant of DP3 that was unable to bind to 14-3-3 but retained 
both the basic region and its nuclear localisation, a series of mutants were made 
that contained amino acid residue changes within the NLS of the protein [Figure 
3.1(i)]. It is known that the various isofonns of 14-3-3 predominantly bind to their 
target ligands via phosphorylated serine residues (Muslin et ah, 1996; Yaffe et aL,
1997). For that reason point mutations were generated in the DP3 plasmid 
constmct. These created serine to alanine substitutions within the NLS of DP3 
[Figure 3.1(i)].
In order to test the ability of each mutant to bind to 14-3-3 in vitro both wt DP3 
and each one of the mutant (2S, 3S, 4S and 5S) were cold in vitro translated 
[Figure 3.2A(ii)] and then incubated with either purified GST alone (negative 
control) or purified GST-14-3-38 [Figure 3.2A(i)], As can be seen from Figure 
3.2A(iii), the amount of the 2S, 3S and 4S mutants binding to 14-3-3 is reduced 
compaied to the amount of wt (compare lanes 1, 3, 5 and 7). Despite this, each of 
these mutants was seen to bind to 14-3-3 whereas the 5S mutant completely lost 
its ability to bind to 14-3-3 (lane 9). None of the DP3 proteins were seen to bind 
GST alone (compare lanes 2, 4, 6 , 8  and 10). This indicated that the binding of the 
DP3 proteins to 14-3-3 was specific. It should be noted that over-expression of 
DP3 in cells results in a doublet that runs at approximately 45KD (see Figure
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3.2C) however it can be seen from Figui'e 3.2A that in vitro translation results in a 
single band. The identity of both DP3 bands is unknown at this time however it is 
postulated that they represent either proteolytic digestion of the upper band or that 
the lower band represents translation from an internal initiating methionine within 
the cDNA. Although this is unlikely, it is possible if leaky translation occurs from 
the first methionine.
It is known that both of these bands do represent DP3 since previous work in the 
laboratory has shown that both bands are competed out with peptide competition 
of the DP3 antibody. The upper band does not represent a phosphorylated fomi of 
DP3 since this band does not disappear upon phosphatase treatment. The presence 
of only one band in Figure 3.2A indicates that, whatever the reason for the DP3 
doublet in vivo, this is not reproduced in vitro. It is known however that this single 
band does represent DP3 since this band is not produced in an in vitro control 
translation.
3.2B: The DP3 5S mutant is unable to bind 14-3-3 in vitro
In order to confirm the result from Figure 3.2A, that the DP3 5S mutant was 
unable to bind 14-3-3, it was decided to use a pull-down system from cell extracts. 
Both the wt DP3 and the 5S mutant were sub-cloned into a GST tagged bacterial 
expression vector (pGEXKG) and the GST tagged DP3 wt and 5S mutant proteins 
were purified [Figure 3.2B(i)]. Transiently transfected COS-7 cells expressing 
myc-tagged 14-3-3 were harvested and lysed in microextraction buffer (as 
described in Materials and Methods).
The cellular extracts were incubated with either GST alone (negative control), 
GST-DP3 wt or GST-DP3 5S mutant. As can be seen fi'om Figure 3.2B(ii) the 14- 
3-3 was seen to bind to only the wt GST DP3 constmct (lane 3) and not the 5S 
mutant (lane 4), with no 14-3-3 being seen to bind to GST alone (lane 2). This 
indicated that the interaction between DP3 and 14-3-3 was specific. This result 
suggested that in vitro at least the DP3 5S mutant was unable to effectively 
complex with 14-3-3 compared to the wt DP3.
3.2C: The DP3 5S mutant is unable to bind 14-3-3 in vivo
To provide evidence that the 5S mutant had lost its ability to bind to 14-3-3 in 
vivo the interaction between those two proteins was assayed by 
immunoprécipitation. Transiently transfected COS-7 cells, expressing myc-tagged 
14-3-38 and either DP3 wt or DP3 5S were harvested, lysed in microextraction 
buffer (as described in Materials and Methods) and the cellular extracts were
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immunoprecipitated with either the rabbit polyclonal DP3 antibody, 7.2 [Figure 
3.2C(i)] or the rabbit polyclonal antibody directed against the epsilon isofomi of 
14-3-3 [Figure 3.2C(ii)].
Figure 3.2C(i) shows that equal amounts of wt and 5S DP3 were 
immunoprecipitated (lanes 5 and 6  respeetively) and these amounts were 
equivalent to the amount of protein in the input (lanes 2 and 3). The amount of 14- 
3-3 present in either complex was remarkably different however. A significant 
amount of 14-3-3 co-precipitated with the wt (lane 5) however no 14-3-3 was 
present in the sample expressing DP3 5S (lane 6 ). No detectable 14-3-3 co­
precipitated with the DP3 antibody alone (lane 4), suggesting that the 14-3-3 seen 
in lane 5 forms a specific complex with wt DP3.
The immunoprécipitation experiment was repeated using the antibody directed 
against 14-3-38 . Again, similar amounts of 14-3-3 were immunoprecipitated 
(lanes 7 and 8 ) when compared to the input lanes (lanes 3 and 4) however the 
amount of DP3 co-immunoprecipitating was significantly different. Comparing 
DP3 levels in lanes 7 and 8  it can be seen that wt DP3 was present in the complex 
with 14-3-3 but that the 5S mutant was not. The control immunoprécipitation 
experiments using the 14-3-3 antibody incubated with either DP3 wt (lane 5) or 
the mutant (lane 6 ) proved negative, implying that the co-immunoprécipitation of 
wt DP3 with 14-3-3 was specific.
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3.2D: Endogenous 14-3-3 and DP2 form a complex
In the literature DP3 and DP2 are the same protein, DP3 being the murine form of 
human DP2. It was of interest to investigate whether DP3 and 14-3-3 could 
interact at an endogenous level however the DP3 antibody, 7.2, had certain 
limitations in that it could not recognise the endogenous DP3 protein. To 
overcome this it was decided to look at the interaction between DP2 and 14-3-3 in 
the human myeloid leukaemia cell line, ML-1. Despite not being able to assay the 
5S mutant for its ability to bind 14-3-3 at an endogenous level, this experiment 
would provide some idea of how physiologically relevant the interaction between 
DP2 and 14-3-3 was.
To test this, the ML-1 cell line was lysed in microextraction buffer and the cell 
extract was subjected to immunoprécipitation with a polyclonal antibody 
specifically directed against the epsilon isofonn of 14-3-3. Detection of DP2 was 
canied out using a monoclonal antibody specific for DP2. Figure 3.2D, lane 4 
shows that DP2 (top track) is forming a complex with 14-3-3 (bottom track) when 
the extract is immunoprecipitated with the 14-3-3s antibody. To ensure that the 
band seen in lane 4 was 14-3-36, peptide competition was carried out. The 14-3-3s 
antibody was incubated with the peptide that it was raised against and this was 
then incubated with the right half of lane 4. It can be seen that this band 
disappears when the antibody is incubated with the peptide and the membrane, 
indicating that this band is 14-3-36. No detectable amounts of either DP2 or 14-3- 
38  were seen to fbnn a complex with a control antibody, implying that the
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interaction between DP2 and 14-3-38 was specific (lane 3, lower and upper tracks 
respectively).
Since no peptide was available to show that the band obseiwed was DP2, it was 
necessary to run the input lane from the endogenous IP against extract with over­
expressed DP3 and 14~3~3s from COS-7 cells. This showed that endogenous DP2 
in ML-1 cells runs at the same size as the upper form of over-expressed DP3 in 
COS-7 cells (compare top track, lanes 1 and 2). Endogenous 14-3-38 in ML-1 
cells runs just below over-expressed 14-3-38, and at the same size as endogenous 
14-3-38, in COS-7 cells (compare bottom track, lanes 1 and 2).
3.2E: The DP3 5S mutant retains nuclear localisation
It has been reported that DP3 is localised in the nucleus due to the fact that it 
contains a bi-partite NLS (de la Lima et al., 1996). Nuclear localisation thereby 
allows a further level of control over E2F (Allen et al., 1997). Since the 5S mutant 
contained changes within the NLS it was necessary to ensure that, before using 
the mutant in further studies, that it retained the ability to localise in the nucleus.
To address this question COS-7 cells were transiently transfected with either the 
wt DP3 protein or the 5S mutant. The cells were then stained with the polyclonal 
7.2 antibody and subjected to immunofluorescence. Figure 3.2E shows that both 
the wt DP3 protein and the 5S mutant were able to effectively localise to the 
nucleus (compare C and D). This result showed that, despite having multiple point
9 2
mutations within its NLS region, the DP3 5S mutant retained the ability to localise 
in the nucleus.
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3.3 CONCLUSIONS
It has recently been shown that effective nuclear localisation of DP3 is dependent 
on its N-terminal bi-partite NLS domain (de la Luna et al., 1996), Subsequent 
work identified this region of DP3 as important in the complex fomiation with the 
14-3-3 family of proteins (Cruickshank, 2000).
Deletion of the basic portion of the NLS resulted in the abrogation of the ability of 
the DP3 protein to bind 14-3-3. However this also resulted in the cytoplasmic 
localisation of DP3 AB. This raised the question of whether 14-3-3 played a role 
in the nuclear localisation of the DP3/E2F complex. Also, to allow further 
investigation of the relationship between DP3 and 14-3-3 it was necessary to 
generate a mutant DP3 that was unable to bind 14-3-3 but still retained the ability 
to accumulate in the nucleus.
Given that 14-3-3 proteins have been shown to bind to their target ligands via 
phosphorylated serine residues (Muslin et al., 1996; Yaffe et al., 1997), it was 
queried whether this was the case with DP3 since the NLS of this molecule 
contained five serines in total. Consequent generation and analysis of a series of 
mutants containing serine to alanine changes within the NLS resulted in the 
identification of a mutant which bears changes to all serines within the known 14- 
3-3 binding region.
Subsequent biochemical analysis of this mutant showed that it was unable to bind 
to 14-3-3 and that, despite the multiple changes made within the bi-partite NLS
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domain of the molecule, it still retained the ability to localise in the nucleus. This 
result provides evidence that one of the roles for 14-3-3 is not in the nuclear 
localisation or retention of DP3. The generation of a nuclear DP3 that is unable to 
bind to 14-3-3 also provides a powerful tool in the understanding of the influence 
that 14-3-3 exerts on the activity of E2F, via the interaction with DP3. 
Furthermore, Figure 3.2D showed that DP2 and 14-3-3 could interact at an 
endogenous level. This was an important result since it showed that this 
interaction is physiologically relevant. Figure 3.1 (ii) provides a tabular overview 
of the properties o f the various DP3 proteins used in the study.
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Figure 3.1: The DP35 Proteins
i. Diagrammatical representation of the DP3Ô proteins used in the study. The 
DP3AB mutant used in the previous study is also shown (Cruickshank, 
2000).
ii. Tabular overview showing the sub-cellular localisation and the ability to 
bind 14-3-3 of each of the DP35 proteins.
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Figure 3.2A: Identification of a DP3 mutant that cannot bind
14-3-3 in vitro
i) Coomassie stain showing bacterially expressed GST (lane 3), GST-14-3-3 (lane 
4) and 2pg and 5pg BSA (lanes 1 and 2 respectively) as protein standards.
ii) Ipg of wt DP3, DP3 2S, 3S, 4S and 5S mutants were cold in vitro translated. 
Input levels of the various DP3 constructs are shown. DP3 was detected using the 
anti-DP3 antibody, 7.2. The * and ** indicate the upper and lower bands of DP3 
respectively,
iii) Equal amounts of each extract were used in a pull-down assay. The samples 
were incubated with either Spg GST (as a negative control) or 5p.g o f GST-14-3- 
3. DP3 was detected using the anti-DP3 antibody, 7.2. The * indicates the upper 
band of DP3.
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Figure 3.2B: The DP3 5S mutant is unable to bind 14-3-3 in vitro
i) Coomassie stain showing bacterially expressed GST (lane 3), GST-DP3 wt 
(lane 4), GST-DP3 58 mutant (lane 5) and 2pg and 5pg BSA (lanes 1 and 2 
respectively) as protein standards.
ii) COS-7 cells were transiently transfected with the following amount of the 
indicated plasmid: 50pg myc-tagged 14-3-3. Around 65 hours post-transfection 
the samples were harvested and used in a pull-down assay. The extracts were 
incubated with either Spg of GST, 5p.g of GST-DP3 wt or 5pg of GST-DP3 5S 
mutant. The exogenous (Ex.) 14-3-3 was detected using the anti-myc antibody.
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Figure 3.2C: The DP3 5S mutant is unable to bind 14-3-3 in vivo
i) COS-7 cells were transiently transfected with the following amounts of the 
indicated plasmids: 20pg DP3 wt, 20pg DP3 5S mutant, 40pg myc-tagged 14- 
3-3 as well as 5pg P-Gal as an internal transfection control (Ex.^Exogenous). 
Around 65 hours post-transfection the samples were harvested and subjected to 
immunoprécipitation with the specific anti-DP3 antibody, 7.2. DP3 was 
detected using the anti-DP3 antibody, 7.2 whilst 14-3-3 was detected using the 
anti-myc antibody. The * and ** indicate the upper and lower bands of DP3 
respectively and the position of the IgG is indicated.
ii) COS-7 cells were transiently transfected with the following amounts of the 
indicated plasmids: 20p.g DP3 wt, 20pg DP3 5S mutant, 40pg myc-tagged 14- 
3-3 as well as 5pg P-Gal as an internal transfection control (Ex.=Exogenous). 
Around 65 hours post-transfection the samples were harvested, and subjected to 
inununoprecipitation with the specific anti-14-3-3s antibody, T16. DP3 was 
detected using the anti-DP3 antibody, 7.2 whilst 14-3-3 was detected using the 
anti-myc antibody. The * and ** indicate the upper and lower bands of DP3 
respectively and the position of the IgG is indicated.
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Figure 3.2D: Endogenous 14-3-3 and DP2 form a complex
ML-1 cells were harvested and subjected to immunoprécipitation with the 
antibody XI6, which is specific for 14-3-3s. Detection of DP2 was carried out 
using the monoclonal anti-DP2 antibody, G12, whilst detection of 14-3-3 was 
carried out using XI6 (Ex.=Exogenous and En .^Endogenous). Control 
immunoprécipitation was carried out using alkaline phosphatase conjugated 
secondary antibody (Promega) (lane 3). Peptide competition between the XI6 
antibody and the peptide that it is raised against was carried out in the right half 
of lane 4 (bottom panel) to ensure that the band seen in the left half of lane 4 
(bottom panel) was endogenous 14-3-3s. Xo show that the bands seen in lane 2 
(upper and lower panels) were indeed endogenous DP2 and 14-3-3s, cell extract 
fi'om COS-7 cells with over-expressed DP3 and myc-14-3-3s was ran next to 
the endogenous extract from the ML-1 cells. Xhis shows that the bands seen in 
lane 2 line up with the bands seen in lane 1. Xhe • indicates an unidentified 
band picked up by the 14-3-3s antibody that may be another isoform of 14-3-3 
that cross-reacts with the antibody. Xhe * and ** indicate the upper and lower 
bands of DP3 respectively.
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Figure 3.2E: The DP3 5S mutant retains nuclear localisation
COS-7 cells were transiently transfected with the following amounts of the 
indicated plasmids: 2pg DP3 wt or 2pg DP3 5S mutant. Around 65 hours post­
transfection the cells were subjected to immunofluorescence. Cellular DNA was 
stained with DAPI (parts A and B) whilst detection of the exogenously (Ex.) 
expressed DP3 was carried out using the polyclonal antibody, 7.2. The assay 
was earned out blind and the data shown is representative of three independent 
experiments. DP3 wt (part C); DP3 5S (part D).
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Chapter 4: Characterisation of the DP3 5S mutant 
4.1: Introduction
The DP3 gene gives rise to at least four distinct splice variants. The a  and ô 
protein products contain the bi-partite NLS whilst the p and y protein products 
contain only the basic portion of this signal, thus rendering them cytoplasmic (de 
la Luna et al., 1996) [Figure 1.2B(i)]. The NLS spans amino acid residues 40-64 
with the DNA binding/dimerisation domains spanning amino acid residues 56-146 
[Figure 3.1(i)].
With the close proximity of these regions it was therefore deemed necessary to 
further characterise the DP3 5S mutant in a series of biochemical assays. This 
would ensure that it possessed properties like the wild type protein in terms of its 
abilities to interact with an E2F partner and to drive an NLS deficient E2F into the 
nucleus. It was therefore necessary to ensure that the only function that the DP3 
5S mutant lacked was its ability to bind to 14-3-3 and that it was not defective in 
any other way that could prejudice the study of the relationship between E2F and 
14-3-3, mediated via DP3.
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4.2 RESULTS
4.2A: The DP3 5S mutant binds E2F5 in vitro
For effective transcriptional activation, E2F exists as a complex between E2F and 
a DP partner (Bandara et al., 1993). It was therefore important to ensure that the 
DP3 5S mutant still retained its ability to complex efficiently with E2F. Previous 
work in the laboratory, exploring the relationship between DP3 and E2F had 
largely involved using E2F5 in the studies. This was because E2F5 is 
constitutively expressed in cells and lacks an NLS. This allowed the investigation 
of the effects of an NLS-containing DP partner on E2F. It was therefore decided 
to use E2F5 in all of the following studies.
We first addressed the interaction between DP3 wt or the 5S mutant and E2F5 in 
vitro using the GST-fusion DP3 wt and 5S mutant previously described [Chapter 
3, Figure 3.2(B)]. Transiently transfected COS-7 cells expressing HA-tagged 
E2F5 were harvested, lysed in microextraction buffer and equal amounts of the 
extract were incubated with either GST alone, GST-DP3 wt or GST-DP3 5S.
As can be seen from Figure 4.2A(ii), although no E2F5 was in complex with GST 
alone (lane 2) equal amounts of the protein were present in a complex with both 
the wt DP3 (lane 3) and the 5S mutant (lane 4). These amounts are roughly equal 
to the amount of input protein (10% of the extract used in each point). From these 
in vitro studies it can be concluded that the 5S mutant is able to bind to E2F5 as 
effectively as wt DP3.
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4.2B: The DP3 5S mutant binds E2F5 in vivo
In order to confirm that the 5S mutant retained its ability to bind to E2F5 in vivo, 
COS-7 cells were transiently transfected with E2F5 expression vector, wt or 5S 
DP3 and P-Gal as an internal control. An immunoprécipitation assay was 
perfoimed using the polyclonal DP3 antibody, 7.2.
Figure 4.2B shows that equal amounts of DP3 wt (lower track, lane 5) or 5S 
mutant (lower track, lane 6) were immunoprecipitated. The amount of E2F5 co- 
immunoprecipitating with both the wt DP3 and the mutant DP3 was the same 
(compare upper track, lanes 5 and 6 respectively). The interaction between DP3 
wt or 5S mutant with E2F5 was specific since there was no detectable E2F5 
binding to 7.2 Ab alone (upper track, lane 4).
The expression levels of DP3 wt and DP3 5S mutant were the same (compare 
lower track, lanes 2 and 3 respectively), as were the E2F5 levels in these samples 
(compare upper track, lanes 2 and 3). This result allowed the conclusion that the 
5S mutant is able to fonn a complex with E2F5 in vivo to a similar level as the wt 
DP3.
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4.2C: The 5S mutant localises E2F5 to the nucleus
The sub-cellular localisation of both E2F4 and E2F5 during the cell cycle differs 
remarkably from that of the other members of the E2F family. E2F4 and E2F5 are 
present in the nucleus predominantly in GO and early G l. During mid-Gl, they 
localise in the cytoplasm (Dyson, 1998). The fact that both of these E2F’s lack an 
intrinsic NLS, which DP3 possesses, points to a level of control that DP3 can 
exert over E2F4 and E2F5, and therefore, gene expression.
In order to ensure that the 5S mutant could still efficiently drive an NLS-deficient 
E2F into the nucleus, COS-7 cells were transiently transfected with E2F5 alone or 
E2F5 and either wt DP3 or the 5S mutant. Immunofluorescence studies were then 
earned out. Figure 4.2C shows that both wt DP3 and the 5S mutant localise to the 
nucleus (compare E and F), a result in accordance with Figure 3.2E.
When expressed alone, E2F5 displayed a cytoplasmic localisation (part G). 
Nuclear localisation of E2F5 could be seen when E2F5 was co-expressed with 
either the wt DP3 or the 5S mutant (compare H and I). This result allowed the 
conclusion that, despite the multiple changes within the bi-partite NLS region of 
the DP3 5S mutant, this protein was still able to drive an NLS deficient E2F 
partner into the nucleus.
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4.2D: E2F5 has no effect on the ability of DP3 to bind to 14-3-3
Taken together, experimental work pursued towards characterising the 5S mutant 
showed that this mutant was still able to act like the wt DP3 in its ability to bind to 
E2F5 and to drive E2F5 into the nucleus. In order to address the question whether 
E2F5 had an effect on the ability of DP3 to bind 14-3-3, COS-7 cells were 
transiently transfected with wt DP3 and 14-3-3 in the presence or absence of E2F5 
expression vector. The cells were harvested and subjected to immunoprécipitation 
with the anti-DP3 antibody, 7.2.
As can be seen from Figure 4.2D, the amount of 14-3-3 being co- 
immunoprecipitated with the wt DP3 is similar iiTespective of the presence of 
E2F5 (compare lanes 5 and 6, bottom track). The amount of DP3 
immunoprecipitated in the presence or absence of E2F5 is unchanged (compare 
lanes 5 and 6, top track). Lanes 1, 2 and 3 show the levels of the input protein. 
Lane 4 shows that no 14-3-3 was present in a complex with the DP3 antibody 
alone, suggesting that the complex fonnations seen in lanes 5 and 6 were specific. 
This result allowed the conclusion that the ability of DP3 and 14-3-3 to form a 
complex is not dependent on the presence or absence of E2F5.
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4.3 CONCLUSIONS
In this chapter a series of experiments were imdeilaken in order to elucidate that 
the DP3 5S mutant was the proper biochemical tool towards analysing in detail 
the functional role of the E2F/DP3/14-3-3 complex. E2F5 was chosen since it is 
highly expressed tlrroughout the cell cycle and lacks an NLS.
The results of this work firstly showed that the DP3 58 mutant could bind to E2F5 
both in vitro and in vivo to a comparable level to that of the wt DP3 protein 
(Figures 4.2A and 4.2B). Importantly this mutant still retained the ability to drive 
the NLS-deficient E2F5 into the nucleus, the same way as the wt DP3 (Figure 
4.2C). Finally E2F5 had no effect on the ability of DP3 to fomi a complex with 
14-3-3 (Figure 4.2D).
The only function that the DP3 58 mutant was proved to be defective in 
comparison with the wt protein was its ability to bind 14-3-3. These results were 
important since they showed that no other property that the DP3 58 mutant 
possessed could prejudice the study of the nature of the relationship between E2F 
and 14-3-3, mediated by DP3.
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Figure 4.2A: The DP3 5S mutant binds E2F5 in vitro
i) Coomassie stain showing bacteriaily expressed and purified GST alone (lane 3), 
GST-DP3 wt (lane 4), GST-DP3 5S mutant (lane 5) proteins and 2|Lig and 5pg 
BSA (lanes 1 and 2 respectively).
ii) COS-7 cells were transiently transfected with the following amount of the 
indicated plasmid: 50pg HA-tagged E2F5. Around 65 hours post-transfection the 
samples were harvested and used in a pull-down assay. The extracts were 
incubated with either 5pg of GST, 5pg of GST-DP3 wt or 5pg o f GST-DP3 5S. 
The exogenous (Ex.) E2F5 was detected using an anti-HA antibody.
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Figure 4.2B: The DP3 5S mutant binds E2F5 in vivo
COS-7 cells were transiently transfected with the following amounts of the 
indicated plasmids: 20pg HA-tagged E2F5, 20pg DP3 wt, 20|iig DP3 5S mutant as 
well as 5pg of (3-Gal as an internal transfection control (Ex.-Exogenous). Around 
65 hours post-transfection the samples were harvested and subjected to 
immunoprécipitation with the DP3 antibody, 7.2. DP3 was detected using 7.2 
whilst the monoclonal anti-HA antibody was used to detect E2F5. The * and ** 
indicate the upper and lower bands of DP3 respectively and the position of the 
IgG is indicated.
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Figure 4.2C: The 5S mutant localises E2F5 to the nucleus
COS-7 cells were transiently transfected with the following amounts of the 
indicated plasmids: 2pg HA-tagged E2F5, 2pg DP3 wild type and 2pg DP3 5S 
mutant. Around 65 hours post-transfection the cells were harvested and subjected 
to immunofluorescence. Cellular DNA was stained with DAPI (parts A-C) whilst 
detection of the exogenously (Ex.) expressed E2F5 and DP3 was carried out using 
a monoclonal anti-HA antibody and the 7.2 polyclonal anti-DP3 antibody 
respectively. The assay was carried out blind and the data shown is representative 
of tliree independent experiments. E2F5 alone (part G); DP3 wt and E2F5 (parts E 
and H); DP3 5S and E2F5 (parts F and I).
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Figure 4.2D: E2F5 has no effect on the ability of DP3 
to bind to 14-3-3
COS-7 cells were transiently transfected with the following amounts of the 
indicated plasmids: 20p.g HA-tagged E2F5, 20pg DP3 wild type, 40pg myc- 
tagged 14-3-3 and 5pg p-Gal as an internal transfection control (Ex.=Exogenous). 
Around 65 hours post-transfection the samples were harvested and subjected to 
immunoprécipitation with the DP3 antibody, 7.2. Detection of DP3 was carried 
out using 7.2, E2F5 was detected by an anti-HA antibody whilst 14-3-3 was 
detected by the anti-myc antibody. The * and ** indicate the upper and lower 
bands of DP3 respectively and the position of the IgG is indicated.
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Chapter 5: 14-3-3 does not alter the sub-cellular 
localisation of E2F/DP3
5.1: Introduction
As previously described in chapter 1, 14-3-3 proteins are able to regulate the 
activity of a wide range of their ligands by altering the sub-cellular localisation of 
the target protein. Examples include the cytoplasmic tethering of cdc25C 
(Kumagai and Dunphy, 1999), cdk2 (Laronga et a l, 2000) and HDAC4 and 
HD AC 5 (Grozinger and Schreiber, 2000). In this way 14-3-3 proteins can 
indirectly influence the activity of target ligands by altering their sub-cellular 
localisation.
Given this it was of interest to examine if the sub-cellular localisation of DP3 was 
altered when co-expressed with 14-3-3 and also whether a lack of binding to the 
DP3 5S mutant influenced the cellular location of 14-3-3. This would allow the 
further understanding of whether 14-3-3 could influence the activity of the 
E2F/DP3 heterodimer by altering the sub-cellular localisation of the complex.
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5.2: RESULTS
5.2A: 14-3-3 unable to bind DP3 localises in the cytoplasm
14-3-3 proteins can regulate the cell cycle by tethering the target ligand in the 
cytoplasm, thereby acting as ‘anchor’ molecules. It is thought that 14-3-3s are 
able to do this by binding near, and thereby interrupting, nuclear localisation 
signals in the target molecule, which prevents the NLS from complexing with the 
nuclear import machinery.
To address the question of whether 14-3-3 could influence the sub-cellular 
localisation of E2F/DP3, COS-7 cells were transiently transfected with plasmids 
expressing myc-tagged 14-3-3 alone or together with both E2F5 and wt DP3 or 
E2F5 and the 5S mutant. The cells were haiwested and subjected to 
immunofluorescence. Figure 5.2A(i) shows that, in accordance with Figure 3.2E, 
wt DP3 localises to the nucleus (parts E and F). When expressed alone, 14-3-3 
displayed a mostly uniform staining pattern throughout the cell (part G). Upon the 
co-expression with wt DP3, 14-3-3 localised mostly in the nucleus (parts H and I) 
and the cellular location of DP3 was not seen to change.
Again, Figure 5.2A(ii) shows that the DP3 5S mutant localised exclusively to the 
nucleus (parts E and F). Interestingly, when 14-3-3 was co-expressed with the 
DP3 5S mutant it localised mostly to the cytoplasm (parts H and I). Taken 
together these results show that 14-3-3 does not act to alter the sub-cellular 
localisation of E2F/DP3. Indeed Figure 5.2(ii) suggests that DP3 may act to drive
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14-3-3 into the nucleus and then act as a nuclear anchor for 14-3-3, since a lack of 
binding to DP3 causes a significant increase in the cytoplasmic localisation of 14- 
3-3. Figure 5.2A(iii) shows the typical example in the nuclear and cytoplasmic 
distribution of 14-3-3 when co-expressed with either wt DP3 or the DP3 5S 
mutant.
5.2B: 14-3-3 unable to bind DP3 can localise to the nucleus
Figure 5.2A(ii) showed that 14-3-3 that was unable to bind the DP3 5S mutant 
predominantly localised in the cytoplasm. This suggested that DP3 was acting as a 
nuclear anchor for 14-3-3. However this did not mle out the possibility that 14-3-3 
could actively shuttle between the nucleus and the cytoplasm and that it was not 
dependent on the binding to DP3 to localise it to the nucleus. To address this point 
it was decided to repeat the experiment carried out in Figure 5.2A with the use of 
leptomycin B, which can block the nuclear export of certain proteins.
COS-7 cells were transiently transfected with plasmids expressing myc-tagged 
14-3-3 alone or together with both E2F5 and wt DP3 or E2F5 and the 5S mutant. 
The cells were treated with leptomycin B and subjected to immunofluorescence. 
Figure 5.2B(i) shows that, when expressed alone, 14-3-3 again displayed a mostly 
unifoim staining pattern (part C). Upon the addition of leptomycin B 14-3-3 was 
seen to accumulate in the nucleus (part D). Upon the co-expression of wt DP3, 14- 
3-3 localised mostly in the nucleus [Figure 5.2B(ii) part E], results that were 
observed previously [Figure 5.2A(i)]. In the presence of leptomycin B 14-3-3 was
124
seen to accumulate in the nucleus (part F). In accordance with previous results, 
when 14-3-3 was co-expressed with the DP3 5S mutant it localised mostly to the 
cytoplasm [Figure 5.2B(iii) part E]. Upon the addition of leptomycin B 14-3-3 
localised exclusively in the nucleus (part F). These results indicate that the nuclear 
localisation of 14-3-3 is not dependent on the binding to DP3 and indeed other 
mechanisms may be involved which allow 14-3-3 to shuttle between the nucleus 
and the cytoplasm, independently of binding to DP3.
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5.3 CONCLUSIONS
The 14-3-3 proteins have been shown to bind to a variety o f proteins critical in 
controlling the mammalian cell cycle and to alter their sub-cellular localisation 
(Fu et al., 2000). However the results shown in this chapter indicate that the 
binding to 14-3-3 does not alter the cellular location of E2F/DP3.
In the presence of wt DP3, 14-3-3 mostly loealises to the nucleus [Figure 5.2A(i) 
parts H and I]. Whilst this was tme for the wt DP3, in the presence of the DP3 5S 
mutant, there was an increase in the cytoplasmic 14-3-3 seen in the cell [Figure 
5.2A(ii) parts H and I]. This was an interesting result since it suggested that, 
rather than 14-3-3 influencing the sub-cellular localisation of DP3, that DP3 could 
have been actively blocking the nuclear export of 14-3-3.
Recent work by Bmnet et a i, 2002 has now shown that 14-3-3 proteins do not 
contain a C-terminal NES, as was previously thought. Indeed, this region of 14-3- 
3 has been shown to be involved in ligand binding (Bmnet et al., 2002). The fact 
that the 14-3-3 that was unable to bind the DP3 5S mutant was localised to the 
cytoplasm suggested two possibilities. Either it was mostly localised to the 
cytoplasm in the first instance and was therefore unable to localise to the nucleus 
since it could not complex with DP3 5S or it was indeed able to enter the nucleus 
and was exported by some other mechanism. This result raised the question of 
whether 14-3-3 was indeed dependent on DP3 for its nuclear localisation or 
whether 14-3-3 could still enter the nucleus itself and that subsequent complex 
fonnation occuiTed in the nucleus.
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Indeed, Figure 5.2B showed that, whilst 14-3-3 localised in the cytoplasm when 
unable to bind DP3 5S, it could still enter the nucleus itself since leptomycin B 
treatment, which blocks nuclear export, caused an accumulation of 14-3-3 in the 
nucleus in the presence of the DP3 5S mutant. This result showed that the nuclear 
localisation of 14-3-3 was not dependent on binding to DP3, rather 14-3-3 seems 
able to independently shuttle in and out of the nucleus.
This allows the conclusion that the nature of the relationship between DP3 and 
14-3-3 may be of a ‘fluid’ nature. If 14-3-3 was dependent on DP3 for its nuclear 
import then this would mean that E2F/DP3 would be targeted to specific promoter 
regions with 14-3-3 already in complex. This could presumably allow 14-3-3 to 
influence the activity of E2F/DP3 without any prior signalling pathway being 
required to induce 14-3-3 to enter the nucleus and to bind to DP3. However, if  14- 
3-3 can enter and exit the nucleus by itself it suggests that the binding between 
DP3 and 14-3-3 could occur once the E2F5/DP3 heterodimer is in the nucleus and 
that some signalling event such as phosphorylation is required to initiate binding.
Figure 5.2B raises the interesting question of how 14-3-3 that is unable to bind to 
DP3 is still able to actively shuttle between the nucleus and the cytoplasm. 
Although the work in chapter 3 showed that the DP3 5S mutant and 14-3-3 are 
unable to form a complex, this does not prove that the interaction is direct. The 
result in Figure 5.2B suggests that there may be another unidentified protein 
within the complex that is still able to bind to 14-3-3 and which possesses both an 
NLS and an NES. This would explain how 14-3-3 that is unable to bind to DP3 is
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able to shuttle between the nucleus and the cytoplasm. It also cannot be ruled out 
that the 14-3-3 that is unable to bind to DP3 is then targeted to other endogenous 
partners that localise it predominantly to the cytoplasm. If this was the case 
however it could be postulated that the same pattern of distribution of 14-3-3 
would be observed when 14-3-3 is expressed alone. However it may be that 14-3- 
3 that is co-expressed with the DP3 5S mutant behaves in a different mamier hom 
14-3-3 that is expressed alone.
Also, despite the fact that the sub-cellular localisation of DP3 is not influenced by 
co-expression with 14-3-3, it camiot be ailed out that this may not happen if some 
sort of intra- or extra-cellular signalling event was to occur.
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Figure 5.2A: 14-3-3 unable to bind DP3 localises in the cytoplasm
i) and ii) COS-7 cells were transiently transfected with the following amounts of 
the indicated plasmids; 2p,g HA-tagged E2F5, 2pg DP3 wt, 2pg DP3 5S mutant, 
4pg myc-tagged 14-3-3. Around 65 hours post-transfection the cells were fixed 
and subjected to immunofluorescence. Cellular DNA was stained with DAPI (i 
and ii, parts A-C) whilst detection of the exogenously (Ex.) expressed 14-3-3 and 
DP3 was carried out using a monoclonal anti-myc antibody and the polyclonal 
anti-DP3 antibody, 7.2, respectively. The assay was carried out blind and 200 
cells were counted. Data shown is representative o f three independent 
experiments. 14-3-3 alone (part G); DP3 wt and 14-3-3 (parts E and H); DP3 5S 
and 14-3-3 (parts F and I).
hi) Graphical representation of the cellular distribution of 14-3-3 in the presence 
of either wt DP3 or the 5S mutant.
129
i)
Ex. [ 14-3-3 DP3 WILD TYPE + E2F5 + 14-3-3
DAPI
DP3
14-3-3
ii)
Ex. [  14-3-3 DP3 5S MUTANT + E2F5 + 14-3-3
DAP!
DP3
14-3-3
100
80
c/5d 60
u
o  40 
20 
0
I NUCLEAR 
I CYTOPI-ASMIC 
NUCLEAR + CYTOPLASM IC
1 I i I I
D P 3  W I L D  T Y P E  D P 3  5 S  M U T A N T
Figure 5.2B: 14-3-3 unable to bind DP3 can localise to the nucleus
i), ii) and iii) COS-7 cells were transiently transfected with the following amounts 
of the indicated plasmids: 2pg HA-tagged E2F5, 2pg DP3 wt, 2pg DP3 5S 
mutant, 4pg myc-tagged 14-3-3. Ai'ound 48 hours post-transfection the cells were 
treated with IpM  leptomycin B (LMB). Around 17 hours later the cells were fixed 
and subjected to immunofluorescence. Cellular DNA was stained with DAPI (i-iii, 
parts A and B) whilst detection of the exogenously (Ex.) expressed 14-3-3 and 
DP3 was carried out using a monoclonal anti-myc antibody and the polyclonal 
anti-DP 3 antibody, 7.2, respectively. The assay was carried out blind and the data 
shown is representative of three independent experiments. 14-3-3 alone (i, part C); 
14-3-3 and LMB (i, part D); DP3 wt and 14-3-3 (ii, parts C and E); DP3 wt, 14-3- 
3 and LMB (ii, parts D and F); DP3 5S and 14-3-3 (iii, parts C and E); DP3 5S, 
14-3-3 and LMB (iii, parts D and F).
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Chapter 6: 14-3-3 has an effect on the cell cycle through 
the E2F pathway
6.1: Introduction
14-3-3 proteins have an integi'al role to play in controlling the mammalian cell 
cycle (Fu et al., 2000). Indeed, 14-3-3 proteins are able to bind to, and regulate, a 
wide variety of proteins involved in control of the cell cycle including cdc25C 
(Peng et al., 1997), Weel (Rothblum-Oviatt et a l,  2001), p53 (Waterman et a l, 
1998) and both HDAC4 and HD AC 5 (Grozinger et al., 2000).
E2F4 and E2F5, which both lack an NLS, are known to negatively regulate the 
cell cycle (Stevens and La Thangue, 2003). In particular, they acquire nuclear 
localisation via one of the pocket proteins and therefore they exert a repressive 
role on the cell cycle (Stevens and La Thangue, 2003). If however, either of these 
E2Fs is in complex with an NLS containing splice variant of the DP3 family, 
activation of cell cycle genes is observed since nuclear localisation is attained 
tluough the DP3 component, (de la Luna et al., 1996) [Figure 1.2B(i)].
It was therefore of interest to examine whether 14-3-3 could exert an influence on 
the cell cycle, via the interaction with the DP3/E2F heterodimer.
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6.2: RESULTS
6.2A: 14-3-3 has an effect on DP3/E2F5 mediated transcriptional
activity in vitro
It was firstly of interest to analyse whether the cytoplasmic localisation of 14-3-3 
in the presence of the DP3 5S mutant had any effect on the cell cycle. To address 
this question the co-activation function of either the wt DP3 or the 5S mutant in 
the presence or absence of 14-3-3 was assayed using a luciferase reporter assay on 
a synthetic E2F5 responsive promoter. Figure 6.2A shows that the luciferase 
activity was low in the samples expressing E2F5 (track 3), DP3 wt (track 4) or 5S 
mutant alone (track 5). The luciferase activity was also low in the samples where 
E2F5 was co-expressed with either DP3 wt (track 12) or the 5S mutant (track 13).
When 14-3-3 was co-expressed with E2F5 and wt DP3 (tracks 14-16), there was a 
significant and titratable increase in the expression of the cyelin-E gene. Indeed, 
when the ratio of transfected 14-3-3 to wt DP3 and E2F5 was 2:1, the amount of 
luciferase activity was around six-fold higher than wt DP3 and E2F5 alone (track 
16). However, when 14-3-3 was titrated on top of E2F5 and the DP3 5S mutant 
(tracks 17-19) only a marginal increase in the expression of the cyclin E reporter 
was obseiwed and no titratable effect was seen. These data suggested that 14-3-3 
has a significant effect on the transcriptional activity of the wt DP3/E2F5 
heterodimer but that it is unable to exert the same effect over the DP3 5S/E2F5 
complex.
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6.2B: 14-3-3 has an effect on DP3/E2F5 mediated 
cell cycle progression
Given the effect of 14-3-3 on the transcriptional activity of the DP3/E2F5 
heterodimer in vitro, it was of interest to see whether this regulation had any 
consequences on the cell cycle in vivo. For this pui*pose, Fluorescence Activated 
Cell Sorting (FACS) analysis was earned out. COS-7 cells were transiently 
transfected with the indicated plasmids shown in Figure 6.2B(i), along with the 
cell surface marker CD20.
Figure 6.2B(i) shows that 14-3-3 alone (part B) is able to cause a partial induction 
of cell cycle progiession over the mock sample (part A). When E2F5 and wt DP3 
are co-expressed together (part C), a decrease in the G1 population is observed 
compared to mock with a slight rise in the G2 population. However, when 14-3-3 
is co-expressed with both E2F5 and wt DP3 (part D) a significant amount of cell 
cycle progression is observed compared to both E2F5 and DP3 alone and the 
mock sample (compare parts A, C and D).
In contrast, when the DP3 5S mutant and E2F5 are co-expressed together only a 
marginal amount of cell cycle progression is observed over the mock (compare 
parts A and E). Strikingly, the co-expression of 14-3-3 with the DP3 5S/E2F5 
heterodimer had only a marginal effect on cell cycle progression compared to DP3 
5S and E2F5 alone or the mock (compare A, E and F). This data allowed the 
conclusion that 14-3-3 has a significant effect on cell cycle progression, mediated 
tlu'ough the regulation of E2F. Importantly, this effect can be seen to be dependent
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on the ability of 14-3-3 to bind to DP3 since the ability of 14-3-3 to cause cell 
cycle progression was impaired when it was co-expressed with E2F5 and the DP3 
5S mutant. These in vivo data therefore substantiate the in vitro results, suggesting 
that 14-3-3 functions as a positive regulator of the transcriptional activity of the 
wt DP3/E2F5 heterodimer and that this effect is dependent on binding to DP3. 
Figure 6.2B(ii) represents the percentage increase in G l, S-phase, G2/M and Sub- 
G1 of each of the samples, relative to the mock.
6.2C: 14-3-3 regulates S-phase entry
Figure 6.2B had provided in vivo evidence that showed that 14-3-3 could 
positively influence cell cyele progression thi'ough its effects on E2F. However 
the FACS data could not provide an accurate observation of the induction of S- 
phase entry, a part of the cell cycle where E2F plays an essential role. It was 
therefore of interest to see if  14-3-3 was regulating the ability of E2F to induce the 
exit fi*om Gl and the entry into S-phase.
In order to analyse the possible effect of 14-3-3 on the entry into S-phase the Brdu 
incorporation method was employed. COS-7 cells were transiently transfected 
with the plasmids indicated in Figure 6.2C as well as red fluorescent protein 
(RFP), to enable transfection efficiency to be measured. The cells were fixed onto 
coverslips, subjected to Brdu incorporation and then an anti-Brdu fluorescent 
antibody was added to allow detection of those cells that had entered S-phase.
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Figure 6.2C (i) shows that around 22% of the cells in the mock sample were in S- 
phase (part 1). No significant induction of S-phase was obseiwed when 14-3-3 was 
expressed alone (part 2). When E2F5 and wt DP3 were co-expressed together 
only a marginal amount of S-phase entry was observed (part 3). However, when 
14-3-3 was co-expressed with E2F5 and wt DP3 (part 4) there was a dramatic 
increase in the number of cells in S-phase compared to E2F5 and wt DP3 together 
and the mock alone. Indeed there was almost a two-fold increase in the niunber of 
S-phase cells in this sample compared to the mock.
In contrast, only a marginal amount of S-phase induction was observed with both 
E2F5 and DP3 5S mutant alone (part 5) and 14-3-3 co-expressed together with 
E2F5 and the DP3 5S mutant (part 6). Taken together these results suggest that 
the role that 14-3-3 plays in the positive regulation of the cell cycle tluough E2F 
is to control the entry into S-phase. Again, the influence that 14-3-3 exerts over 
E2F is dependent on its ability to bind to the DP3 component of the heterodimer. 
Figure 6.2C(ii) represents the percentage increase in S-phase o f each of the 
samples, relative to the mock.
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6.3 CONCLUSIONS
A large body of evidence has been published recently regarding the involvement 
of 14-3-3 in the p53 pathway. In particular, 14-3-3 enhances p53 transcriptional 
activity by increasing the affinity of this transcription factor for the DNA 
(Wateiman et a l, 1998). It was therefore interesting to test whether 14-3-3 had 
any effect on E2F5 transcriptional activity in a similar mamier. hideed this was 
proved to be the case since a titration of 14-3-3 over the wt DP3/E2F5 
heterodimer caused a considerable increase in the transcriptional activity of E2F5 
measured on a known E2F responsive gene. This was not the case when 14-3-3 
was titrated on top of the DP3 5S mutant/E2F5 complex, since only a marginal 
effect was observed under these conditions (Figure 6.2A). This result suggested 
that, in vitro at least, that 14-3-3 can exert a positive influence on the 
transcriptional activity of E2F, via DP3.
The data presented in Figure 6.2B also suggested that 14-3-3 could exert a 
positive influence over E2F-mediated transcriptional activity in vivo. 14-3-3 was 
seen to induce a significant level of cell cycle progression over the mock when co­
expressed with E2F5 and wt DP3 however this effect was not repeated when 14- 
3-3 was co-expressed with E2F5 and the DP3 5S mutant. This result suggested 
that 14-3-3 can cause efficient cell cycle progression only when it is able to 
efficiently complex with DP3. hiterestingly, previous evidence indicates that the 
14-3-3 family largely exerts a negative influence on the mammalian cell cycle. 
This result highlighted the possibility that the influences exerted by the 14-3-3 
family over the cell cycle may be isoform specific since the 14-3-3cj isoform plays
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a large part in the negative regulation of cell cycle progi'ession thi'ough its 
regulation of both cdc2 and p53.
Given that E2F is Imown to play a crucial role in the transition from Gl into S- 
phase it was thought that perhaps 14-3-3 was influencing the induction of S- 
phase, mediated by DP3/E2F5. Indeed Figure 6.2C shows that when 14-3-3 is 
able to fonn a complex with the DP3/E2F5 heterodimer, there is around a two­
fold increase in the number of cells in S-phase. This phenotype was not 
reproduced when 14-3-3 was co-expressed with E2F5 and the DP3 5S mutant. 
Also, no significant increase in S-phase entry was seen with either the wild type 
or the mutant complex alone suggesting that the presence of 14-3-3 is essential in 
allowing efficient S-phase progression. These results were slightly in contrast to 
those obseiwed with the FACS data attained in Figure 6.2B, where no significant 
increase in S-phase was observed. However, the Brdu assay provides a far more 
accurate measurement of S-phase than FACS analysis.
Taken together these data suggest an integi'al role for 14-3-3 in the control of the 
mammalian cell cycle and specifically, control of the Gl/S transition, through the 
E2F pathway. Whether the positive effects seen on the eell cyele are due to an 
enlianced level of DNA binding by the wild type DP3/E2F5 heterodimer, 
mediated by 14-3-3, is unclear. However, given the effects that 14-3-3 can exert 
on p53 DNA binding, this is a possibility. It ean however be seen from analysis of 
the effects of 14-3-3 over E2F5 and wt DP3 that 14-3-3 can exert a positive
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influence on the mammalian cell cycle, tlirough E2F, and that this effect is 
dependent on the binding to the DP3 sub-unit.
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Figure 6.2A: 14-3-3 has an effect on DP3/E2F5 mediated 
transcriptional activity in vitro
COS-7 ceils were transiently transfected with the following amounts of the 
indicated plasmids as follows: 0.5pg cyclin-E reporter, Ipg HA-tagged E2F5, Ipg 
DP3 wt, Ipg DP3 5S mutant, 0.5,1 and 2pg of myc-tagged 14-3-3 as a titration 
and Ipg P-Gal as an internal transfection control. Where no 14-3-3 titration is 
indicated, Ipg of 14-3-3 was transfected. Around 65 hours post-transfection the 
cells were harvested and subjected to the luciferase reporter system. The data 
shown is representative of tliree independent experiments and the values depict 
the relative level of luciferase to (3-Gal expression. Each point was done in 
duplicate plates.
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Figure 6.2B: 14-3-3 has an effect on DP3/E2F5 mediated
cell cycle progression
i) COS-7 cells were transiently transfected with the following amounts of the 
indicated plasmids: 5pg CD20, 5pg HA-tagged E2F5, Spg DP3 wt, 5pg DP3 5S 
mutant and lOpg of myc-tagged 14-3-3. Around 65 hours post-transfection the 
cells were harvested and subjected to FACS analysis. Cellular sorting and analysis 
was carried out using a Fluorescence Activated Cell Sorter. The data shown is 
representative of tliree independent experiments. Sub-Gl, G l, S-phase and G2/M 
percentages are shown inset.
ii) Graphical representation, from one of the three independent experiments, of the 
percentage increase in G l, S-phase, G2/M and Sub-Gl of each sample, relative to 
mock.
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Figure 6.2C: 14-3-3 regulates S-phase entry
i) COS-7 cells were transiently transfected with the following amounts o f the 
indicated plasmids: 2pg HA-tagged E2F5, 2pg DP3 wt, 2p.g DP3 5S mutant, 4pg 
myc-tagged 14-3-3 and Ipg RFP. Around 65 hours post-transfection the cells 
were harvested and subjected to Brdu treatment. Detection of the total cell 
population was achieved by staining the cellular DNA with DAPI. The assay was 
carried out blind and 200 cells were counted. The values shown represent the 
average of three separate experiments.
ii) Graphical representation, from one o f the three independent experiments, of the 
percentage increase in S-phase of each sample, relative to mock.
150
i)
M O C K
E 2 F 5
D P 3  W I L D  T Y P E  
D P 3  5 S  M U T A N T  
1 4 - 3 - 3
ii)
Lu
2  3
E 2 F 5
D P 3  W I L D  T Y P E  
D P 3  5 S  M U T A N T  
1 4 - 3 - 3
OS
2u>H
Uctu
<
aiuS
+ + +
1 5
12
9
6
3
0
- 3
-6
- 9
-12
- 1 5
Chapter 7: 14-3-3 regulates DP3/E2F5 mediated apoptosis 
7.1: Introduction
As in cell cycle control and signal transduction, the 14-3-3 proteins have a major 
function in the control of apoptosis (van Hemert et a l, 2001). 14-3-3 proteins are 
seen to negatively regulate pro-apoptotic proteins such as Bad (Zha et a l,  1996), 
FICHRLl (Brunet et a l,  1999) and ASKl (Zhang et a l ,  1999). The regulation of 
these proteins results in the inhibition of apoptosis and 14-3-3 proteins are therefore 
seen as molecules that are intricately involved in the anti-apoptotic effect.
hi addition to its role in proliferation, E2F1 can also trigger apoptosis (Stevens and 
La Thangue, 2003). E2F1 has now been shown to induce the expression of various 
pro-apoptotic proteins such as Apaf-1 (Moroni et a l ,  2001), the p53 homologue, p73 
(hwin et a l ,  2000) and p i4"^^ (Bates et a l ,  1998). It is not loiown whether other 
E2F family members are involved in the regulation of apoptosis. However, recent 
work has shown that E2F5 can induce apoptosis dependent on the nuclear localisation 
of the protein and the presence of a functional transcriptional activation domain 
(Loughran and La Thangue, 2000). Interestingly an intact DNA binding domain 
within the DP3 partner used in the study augmented this apoptotic effect.
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Based on these findings, and the fact that many studies have now documented the 
role of 14-3-3 in the regulation of apoptosis, it was of interest to examine if 14-3-3 
could influence the apoptotic effects of E2F5 tluough DP3. The experimental 
approach implemented to understand this 14-3-3 function is described in this chapter.
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7.2: RESULTS
7.2A: 14-3-3 inhibits DP3/E2F5 mediated apoptosis
In order to examine the role of 14-3-3 in the regulation of apoptosis via the DP3/E2F 
heterodimer the TUNEL (TdT-mediated djUTP-X nick end labelling) assay was used. 
This method is used to detect apoptotic cells and can distinguish between apoptosis 
and other types of cell death such as necrosis.
Figure 7.2A(i) shows that, when transfected alone, 14-3-3 could induce around a 3- 
fold increase in apoptosis over mock (part 1). The amount of apoptosis induced by 
the wt DP3/E2F5 heterodimer was twenty times higher than the mock (part 2), a 
result consistent with data published recently (Louglman and La Thangue, 2000). Co­
expression of E2F5 and the DP3 5S mutant exerted the same apoptotic effect (part 4).
However the amount of apoptosis observed differed quite remarkably between these 
samples when 14-3-3 was co-transfected. Whereas 14-3-3 was seen to considerably 
inliibit apoptosis mediated by the wt DP3/E2F5 heterodimer (part 3) it did not have 
any significant effect on the apoptosis mediated by the DP3 5S/E2F5 heterodimer 
(part 5). Rather, a slight increase in apoptosis over DP3 5S/E2F5 alone was obseiwed. 
These data indicate that the DP3/E2F5 heterodimer has a potent pro-apoptotic 
function, which can be negatively regulated by 14-3-3. The data suggests that 14-3-3 
inhibits the DP3/E2F5 dependent apoptosis, presumably tlu'ough its DP3 binding
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activity since this inliibitory effect is not obsei*ved with the DP3 5S mutant/E2F5 
heterodimer, which is unable to bind 14-3-3.
7.2B: 14-3-3 anti-apoptotic effect is transcription independent
It has recently been shown that the apoptotic effect of E2F5 is linlced to the presence 
of the transcriptional domain (Lougluan and La Thangue, 2000). With this in mind it 
was therefore of interest to analyse the ability of 14-3-3 to inliibit apoptosis induced 
by a TrAnscriptionally Dead E2F5 (TAD E2F5) mutant. If similar patterns were 
observed as in TUNEL carried out with the wt E2F5 then it could be concluded that 
14-3-3 reduces DP3/E2F5 mediated apoptosis independently o f the transcriptional 
domain of E2F5.
Figure 7.2B shows that, in accordanee with the findings reported by Loughran and La 
Thangue, (2000), the levels of apoptosis in cells expressing TAD E2F5 was reduced 
in comparison with cells transfected with the transcriptionally active wt E2F5 
(compare Figure 7.2A parts 2-5 with Figure 7.2B parts 2-5). Again, 14-3-3 alone 
caused around a tlu’ee-fold increase in apoptosis compared to the mock sample (part 
1). The apoptotic pattern remained the same in the samples expressing TAD E2F5 
and either wt DP3 (part 2) or the 5S mutant (part 4) or when 14-3-3 was co­
transfected (parts 3 and 5 respectively). In particular, addition of 14-3-3 significantly 
reduced the wt DP3/E2F5 dependent apoptosis (part 3) but it had no effect on 
apoptosis mediated by the DP3 5S mutant/E2F5 complex (part 5), which again
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showed a slight increase. These data suggest that the observed inhibitory effect of 14- 
3-3 on the DP3/E2F5 mediated apoptosis is exerted in a manner which is independent 
of the transcriptional activity of the complex.
7.2C: 14-3-3 affects the stability of the DP3/E2F5 heterodimer
The data presented so far in Figures 7.2A and 7.2B showed that 14-3-3 could 
negatively regulate the pro-apoptotic effect of the wt DP3/E2F5 heterodimer and that 
this effect was independent of the transcriptional activity of E2F5. One possibility for 
the regulation of DP3/E2F5 mediated apoptosis by 14-3-3 could be the stability of the 
proteins involved. To examine this, COS-7 cells were transiently transfected with the 
plasmids indicated in Figure 7.2C parts i, iii, v and vii. The cells were treated with 
cycloheximide, which inliibits protein synthesis, thereby allowing measurement of 
the degradation profile (persistence in the cell) of the transfected proteins.
Figure 7.2C(i) shows that E2F5 had a persisted in the cell past 150 minutes (part A). 
The upper form of DP3 also persisted past 150 minutes (part B)] whilst the lower 
fonn persisted past 90 minutes (part B). Co-transfection of 14-3-3 had a considerable 
effect on the stability of both DP3 and E2F5. The stability of the lower form of wt 
DP3 and the upper form was reduced compared to expression in the absence of 14-3- 
3 [Figure 7.2C(iii)(B)]. Similarly, the stability of E2F5 was also redueed compared to 
expression in the absence of 14-3-3 (part A).
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Figure 7.2C(v)(A) shows that E2F5, in the presence of the DP3 5S mutant still 
persisted in the cell over 150 minutes. However both forms of the 5S mutant had 
extended stability’s compared to the wt protein [compare Figure 7.2C(i)(B) and 
Figure 7.2C(v)(B)]. Furthermore, the influence that 14-3-3 exerted on the stability of 
both E2F5 and wt DP3 was not obseiwed when 14-3-3 was co-expressed with E2F5 
and the DP3 5S mutant [compare Figure 7.2C (iii)(parts A and B) with Figure 
7.2C(vii)(parts A and B)]. Interestingly, the persistence of 14-3-3 was extended when 
it was co-expressed with E2F5 and the DP3 5S mutant [compare Figure 7.2C(iii)(part 
C) with Figure 7.2C(vii)(part C)]. Taken together these data suggest that 14-3-3 plays 
an essential role in the regulation of the stability of the DP3/E2F5 complex and that 
this regulation is dependent on the ability o f 14-3-3 to bind the DP3 component o f the 
DP3/E2F5 heterodimer.
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7.3 CONCLUSIONS
Given the intricate roles that both E2F and 14-3-3 play in the regulation of apoptosis, 
it was interesting to see if 14-3-3 could affect the DP3/E2F5-mediated apoptotic 
response.
TUNEL analysis showed that 14-3-3 negatively regulates the levels of apoptosis 
induced by the wild type DP3/E2F5 but not the DP3 5S mutant/E2F5 heterodimer. 
Indeed, the levels of apoptosis observed when 14-3-3 was co-transfected with DP3 5S 
and E2F5 were around four-fold higher than when 14-3-3 was co-expressed with wt 
DP3 and E2F5. Interestingly co-transfection of 14-3-3 with the DP3 5S mutant and 
E2F5 resulted in a slight increase of the apoptotic population compared to the DP3 5S 
mutant and E2F5 alone. This could be attributed to the 14-3-3 that is unable to bind 
the DP3 5S mutant acting in the same manner as when 14-3-3 is expressed alone. 
Indeed, the extra apoptosis observed is approximately equal to that seen when 14-3-3 
is expressed alone. It may also be that this extra apoptotic effect is perhaps due to an 
as of yet undefined function of the 14-3-3 that cannot bind to the DP3/E2F5 
heterodimer through inactivation (by re-localisation to the cytoplasm) of an anti- 
apoptotic protein. Indeed, Figure 5.2A(ii) highlighted the fact that most 14-3-3 in the 
presence of the DP3 5S mutant/E2F5 complex re-localised to the cytoplasm.
Recent work has shown that E2F5 can induce apoptosis in a manner dependent on its 
nuclear localisation and the presence of an intact transcriptional domain (Louglrran
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and La Thangue, 2000). In order to investigate whether 14-3-3 regulates DP3/E2F5 
mediated apoptosis in a manner dependent on the transcriptional domain, the 
TUNEL assay was repeated with a transcriptionally dead E2F5 (TAD E2F5). 
Although the levels of apoptosis were reduced under these conditions (as expected), 
the pattern of apoptosis remained the same. 14-3-3 inhibited the apoptosis induced by 
E2F5 and wt DP3 but it did not have any effect when co-expressed with E2F5 and the 
DP3 5S mutant. Again, the sample expressing 14-3-3, E2F5 and the DP3 5S mutant 
showed around a four-fold increase in apoptosis compared to when 14-3-3 was co­
expressed with wt DP3 and E2F5. Under these conditions the same slight increase in 
the apoptotic population was observed suggesting that the 14-3-3 that is unable to 
complex with the DP3 5S mutant causes an increase in apoptosis tlrrough an 
unknown mechanism. This result allowed the conclusion that 14-3-3 is able to 
regulate the levels of apoptosis induced by wt DP3 and E2F5 in a manner that is 
independent of the presence of the transcriptional domain of E2F.
In order to investigate further the mechanism by which 14-3-3 regulates the 
DP3/E2F5 dependent apoptosis the possibility that 14-3-3 inliibits this apoptotic 
pathway by destabilising the DP3/E2F5 complex was analysed. Analysis of the 
persistence in the cell of both the wt DP3/E2F5 and the 5S mutant/E2F5 complexes in 
the absence and the presence of 14-3-3 showed that 14-3-3 was able to reduce the 
stability of the wt DP3/E2F5 heterodimer. However 14-3-3 was unable to affect the 
levels of the DP3 5S mutant/E2F5 complex. This is presumably because 14-3-3 is 
unable to effectively complex with DP3. The results obtained in Figure 7.2C suggest
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that 14-3-3 is essential in regulating the stability of both E2F5 and DP3 and that this 
regulation is dependent on the ability of 14-3-3 to bind DP3.
Recent reports suggest that E2F1 associates with cyclin A during S-Phase. This 
results in DPI phosphorylation and the subsequent loss of the DNA binding aetivity 
of E2F1 due to phosphorylation in the DNA binding domain (Ki*ek et al., 1995). This 
process thereby allows a tight control over the transcriptional activity of proteins that 
are involved in cell cycle progression. Improper regulation of such proteins leads to a 
mis-regulated cell cycle and, ultimately, apoptosis.
It is possible that apoptosis induced by the DP3 5S mutant/E2F5 heterodimer is a 
result of an enlianced stability of the complex on the DNA. Cells unable to regulate 
the protein levels of transcription factor complexes bound to DNA activate 
programmed cell death. Presumably one of the main roles of 14-3-3 is therefore to 
regulate the levels of such complexes by linking them to the ubiquination and 
subsequent degiadation process.
14-3-3 protein levels also seem to be under similar regulation since 14-3-3 protein 
levels were reduced in the presence of the wild type but not the mutant DP3/E2F5 
complex. This is another indication that 14-3-3 acts as a linlcer molecule between the 
protein degradation process and the DP3/E2F5 heterodimer. Indeed, 14-3-3s often act 
as adaptor proteins, bringing and holding together different protein complexes (Fu et 
al., 2000).
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Another interesting observation was that the upper fonn of DP3 had enlianced 
stability compared to the lower fonn. Although 14-3-3 could regulate the stability of 
all the foims of DP3, the levels of the upper fonn were not affected to the same extent 
compared to the lower fonn of the protein. As described in chapter 3 it is not Icnown 
exactly what both forms of DP3 represent. Indeed it may be that if  the lower band is a 
smaller form of DP3 due to tryptic digestion then this may explain why this form may 
be less stable as is shown in the cycloheximide treatment. This therefore points to an 
additional level of control that 14-3-3 can exert over the DP3/E2F complex, based, 
not only on the choice o f DP partner, but also on the distinction of DP3 protein forms 
that are in complex with E2F.
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Figure 7.2A: 14-3-3 inhibits DP3/E2F5 mediated apoptosis
i) COS-7 cells were transiently transfected with the following amounts of the 
indicated plasmids: 2p,g HA-tagged E2F5, 2pg DP3 wt, 2pg DP3 5S mutant, 4pg 
myc-tagged 14-3-3 and Ipg RFP. The cells were harvested, fixed onto coverslips and 
subjected to the TUNEL assay. The assay was carried out blind and 200 cells were 
counted. The amount of apoptosis is presented as fold increase over mock and the 
data shown is the average o f three independent experiments.
ii) Tabular data representing the values of one of the three experiments carried out.
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Figure 7.2B: 14-3-3 anti-apoptotic effect is transcription independent
i) COS-7 cells were transiently transfected with the following amounts of the 
indicated plasmids: 2p,g TAD HA-tagged E2F5, 2pg DP3 wt, 2pg DP3 5S mutant, 
4|.ig myc-tagged 14-3-3 and lp,g RFP. The cells were harvested, fixed onto coverslips 
and subjected to the TUNEL assay. The assay was carried out blind and 200 cells 
were counted. The amount of apoptosis is presented as fold increase over mock and 
the data shown is the average of three independent experiments.
ii) Tabular data representing the values o f one of the three experiments carried out.
164
i)
T A D  E 2 F 5  
D P 3  W I L D  T Y P E  
D P 3  5 S  M U T A N T  
1 4 - 3 - 3
ii)
SAMPLE TRANSFECnON 
EFFICIENCY (%)
TUNEL POSITIVE 
CELLS(%)
TUNELPOSTTIVE CELLS RELATIVE 
TO TRANSFEaiON EFFICIENCY (%)
MOCK 20 1 5
1 1 413 10 3 16.7
2 DP3W1LDTYPE+TADE2E5 20 5 25
3 D P3W 1LDTYPE+TADI2F5+1413 10 2 11.1
4 DP3MUTANT+TADE2F5 10 5 m
5 DP3M IITANT+TADE2F5+1413 13 5 305
Figure 7.2C: 14-3-3 affects the stability of the DP3/E2F5 heterodimer
i) COS-7 cells were transiently transfected with the following amounts of the 
indicated plasmids: 5p g  HA-tagged E2F5 and 5|Lig DP3 wt. The cells were treated 
with cycloheximide (CX) and then harvested at the indicated time points, DP3 was 
detected using the polyclonal antibody, 7.2 and E2F5 with monoclonal anti-HA. The 
* and ** indicate the upper and lower bands of DP3 respectively.
ii) Graphical representation of the stability o f the indicated proteins.
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Figure 7.2C: 14-3-3 affects the stability of the DP3/E2F5 heterodimer
iii) COS-7 cells were transiently transfected with the following amounts of the 
indicated plasmids: 5pg HA-tagged E2F5, 5pg DP3 wt and lOpg myc-tagged 14-3-3. 
The cells were treated with cycloheximide (CX) and then harvested at the indicated 
time points. DP3 was detected using the polyclonal antibody, 7.2, E2F5 with 
monoclonal anti-HA and 14-3-3 with monoclonal anti-myc. The * and ** indicate the 
upper and lower bands of DP3 respectively.
iv) Graphical representation of the stability o f the indicated proteins.
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Figure 7.2C: 14-3-3 affects the stability of the DP3/E2F5 heterodimer
v) COS-7 cells were transiently transfected with the following amounts of the 
indicated plasmids: 5pg HA-tagged E2F5 and 5p,g DP3 5S mutant. The cells were 
treated with cycloheximide (CX) and then harvested at the indicated time points. DP3 
was detected using the polyclonal antibody, 7.2 and E2F5 with monoclonal anti-HA. 
The * and ** indicate the upper and lower bands of DP3 respectively.
vi) Graphical representation of the stability of the indicated proteins.
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Figure 7.2C: 14-3-3 affects the stability of the DP3/E2F5 heterodimer
vii) COS-7 cells were transiently transfected with the following amounts of the 
indicated plasmids: 5p.g HA-tagged E2F5, 5pg DP3 5S mutant and lOjag myc-tagged 
14-3-3. The cells were treated with cycloheximide (CX) and then harvested at the 
indicated time points. DP3 was detected using the polyclonal antibody, 7.2, E2F5 
with monoclonal anti-HA and 14-3-3 with monoclonal anti-myc. The * and ** 
indicate the upper and lower bands of DP3 respectively.
viii) Graphical representation of the stability of the indicated proteins.
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Chapter 8: The DP3/14-3-3 interaction is DNA damage 
responsive
8.1: Introduction
14-3-3 proteins are intricately involved in the DNA damage response. 14-3-3a is 
able to re-localise cdc2 to the cytoplasm after DNA damage and thereby prevent 
mitotic onset (Chan et aL, 1999). Qi and Martinez, (2003) also showed that 
following irradiation, 14-3-3(^ associates with cdc25C, resulting in G2 checkpoint 
activation. These results show that various isoforms of 14-3-3 are essential in 
preventing improper cell cycle progi'ession following DNA damage.
Given the essential role played by E2F in the response to cellular insults, it was of 
great interest to investigate whether the relationship between 14-3-3 and DP3/E2F 
was DNA damage responsive. The purpose of this chapter was to examine if this 
was the case.
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8.2: RESULTS
8.2A: The DP3/14-3-3 interaction is DNA damage responsive
We analysed whether the binding between DP3 and 14-3-3 was responsive to 
DNA damage. To address this, COS-7 cells were transiently transfected with the 
plasmids indicated in Figure 8.2A. The cells were treated with etoposide, which 
induces double stranded breaks in the DNA, and then harvested and subjected to 
immunoprécipitation with the anti-DP3 antibody, 7.2.
Figure 8.2A clearly shows that less 14-3-3 was seen to co-immunoprecipitate with 
DP3 after the cells had been treated with etoposide (compare lower track, lanes 7 
and 8). Specifically, there was a reduction in the amount o f 14-3-3 in complex 
with DP3 after DNA damage. Comparing the upper track, lanes 7 and 8, it can 
clearly be seen that equal amounts of DP3 were immunoprecipitated with the anti- 
DP3 antibody. This implied that the reduction observed in the levels of 14-3-3 in 
lane 8 was not due to a reduction in the amount of DP3 being immunoprecipitated 
in that sample.
Incubation of the anti-DP3 antibody with 14-3-3 before and after damage (lower 
track, lanes 5 and 6) did not result in any 14-3-3 forming a complex with the 
antibody alone, suggesting that the complex formation between DP3 and 14-3-3 
was specific. This result therefore suggested that the interaction between DP3 and 
14-3-3 was responsive to DNA damage and, specifically, that the interaction
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between these two proteins was reduced following treatment with the DNA 
damaging agent, etoposide.
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8.3: CONCLUSIONS
Although only a preliminary result, Figure 8.2A provides some indication that the 
regulation that 14-3-3 exerts over E2F, via DP3, is regulated by the response to 
DNA damage. Specifically, the level of binding between these two proteins is 
reduced following double strand breaks in the DNA. Interestingly, this would 
imply that, following cellular insults, 14-3-3 dissociates from DP3. This would 
presumably produce the same phenotypes obseiwed with the DP3 5S mutant, 
which caused a negative regulation on the cell cycle and an increase in apoptosis.
This would certainly seem to be an advantageous situation for the cell, which 
would need to be able to tightly regulate cell cycle progression following DNA 
damage. Also, if  unable to efficiently repair the damage, the cell would need to 
initiate the apoptotic response. The result presented in Figure 8.2A would 
therefore certainly seem to support this idea. Despite this, more work is required 
to analyse if indeed the interaction between DP3 and 14-3-3 forms part of a 
checkpoint control mechanism.
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Figure 8.2A: The DP3/14-3-3 interaction is DNA damage
responsive
COS-7 cells were transiently transfected with the following amounts of the 
indicated plasmids: 20pg DP3 wt, 40pg myc-tagged 14-3-3 as well as 5pg (3-Gal 
as an internal transfection control (Ex.^Exogenous). Around 50 hours post­
transfection the indicated samples were treated with etoposide. Around 15 hours 
later the samples were harvested and subjected to immunoprécipitation with the 
specific anti-DP 3 antibody, 7.2. DP3 was detected using 7.2 whilst detection of 
14-3-3 was carried out using a monoclonal anti-myc antibody. The * and ** 
indicate the upper and lower bands of DP3 respectively and the position of the 
IgG is indicated. The assay was canied out twice.
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Chapter 9: Discussion 
9.1: The association of E2F and 14-3-3 mediated by DP3
The activity of the E2F transcription factor complex is regulated in a number of 
different ways. These include regulation by the RB family (Flelin et al., 1993), 
phosphorylation by ATM/ATR (Lin et al., 2001) and the cyclin/cdk complexes 
(Krek et a l,  1995; Xu et al., 1994; Guida and Zhu, 1999) and acétylation (Moms et 
al., 2000; Martinez-Balbas et al., 2000). This study has now shown that the activity 
of E2F can be regulated by the 14-3-3 family of signalling molecules, tlirough the 
DP3 partner. Specifically 1 have shown that 14-3-3 can regulate E2F-dependent cell 
cycle progression and apoptosis tlrrough the DP3 component.
The activity of the E2F heterodimer is dependent on its ability to accumulate in the 
nucleus. Since E2F4 and E2F5 lack an NTS and require to be in complex with a 
pocket protein to enter the nucleus (Allen et al., 1997; Verona et al., 1997), this 
creates a repressive E2F complex. However, work by de la Luna et al. (1996) 
showed that E2F4 or E2F5 could enter the nucleus in a transcriptionally active state 
by the choice of DP partner. If in complex with either DP3 a  or S, an E2F lacking 
an intrinsic NLS was driven into the nucleus. This was dependent on the N-terminal 
bi-partite NLS present in both DP3a and DP3Ô. This NLS contained a basic region 
present in all four DP3 splice variants and an extra (E) region directly N-terminal of 
the basic region [Figure 1.2B(i)].
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Subsequent work in the laboratory showed that removal of the basic region resulted 
in the cytoplasmic accumulation of DP3 but that this mutant (termed DP3AB) could 
not be re-localised to the nucleus with an NLS-containing E2F. The re-localisation 
of DP3AB was possible with a non-NLS containing E2F, complexed with a pocket 
protein suggesting that downstream E2F functions are regulated differently after 
pocket protein-mediated nuclear transport compared with free E2F nuclear 
transport (Cruickshanlc, 2000).
With a view towards understanding the role of the DP sub-unit in the E2F/DP 
heterodimer it was reasoned that the basic region of DP3 was involved in regulating 
the interaction of the DP sub-unit with another protein. By employing a yeast two- 
hybrid screen it was found that 14-3-3e could bind to DP3, via the basic region. 
Subsequent biochemical analysis confirmed the interaction and, interestingly, it was 
shown that 14-3-3 was unable to complex with E2F5, suggesting that 14-3-3 
influences E2F activity indirectly, tlirough the DP3 partner. It was subsequently 
shown that the wild type DP3 protein and 14-3-3 could co-localise in the nucleus 
(Cmickshank, 2000).
Given that the interaction was mediated tlu'ough the basic region, this posed the 
question of whether 14-3-3 was influencing the nuclear localisation of E2F, via the 
interaction with the basic region of DP3 or whether the bi-partite NLS was solely 
responsible for the nuclear accumulation o f the E2F/DP3 heterodimer. 14-3-3s are 
known to alter the sub-cellular localisation of a variety of target ligands including
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cdc25C (Peng et al., 1997), HDAC4 and HDAC5 (Grozinger and Schreiber, 2000) 
and cdc2 (Chan et ah, 1999).
The 14-3-3 binding site in cdc25C is located near a bi-partite NLS (Peng et ah, 
1997) which is prevented from associating with the importin a/[3 machinery by 14- 
3-3 (Zeng and Piwnica-Worms, 1999; Kumagai and Diinphy, 1999). In this way, 
14-3-3 can affect the sub-cellular localisation o f some of its ligands by altering such 
signals. Given this, it was of interest to firstly ask whether 14-3-3 was affecting the 
nuclear accumulation of DP3, via the interaction with the basic region within the 
bi-partite NLS o f DP3.
Given that the vast majority of 14-3-3 ligands are bound via phosphorylated serines 
(Fu et ah, 2000) it was queried whether this was the case with DP3. The bi-partite 
NLS of DP3 contains five serine residues (Figure 3.1). Subsequent in vitro 
biochemieal analysis of the ability of 14-3-3 to bind a range of DP3 mutants 
bearing a combination of serine to alanine changes resulted in the identification of a 
mutant that was unable to bind to 14-3-3 (Figure 3.2A). This mutant had changes to 
all five serine residues and was termed the 5S mutant. The 5S mutant was then 
shown to be defective in its ability to bind to 14-3-3 in both a pull-down system 
(Figure 3.2B) and in an in vivo IP (Figure 3.2C). Importantly, the 5S mutant was 
able to localise to the nucleus (Figure 3.2E). This result showed that 14-3-3 does 
not influence the nuclear localisation of DP3. Interestingly, further biochemical 
analysis (Figure 3.2D) showed that 14-3-3 and DP2, the human form of DP3,
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fonned a complex at an endogenous level. This pointed to the conclusion that the 
interaction between DP2 and 14-3-3 was physiologically relevant.
Further characterisation of the DP3 5S mutant revealed that it was only defective in 
its ability to bind 14-3-3 and yet behaved like the wild type protein in every other 
respect (Figures 4.2A-D). Interestingly, it was shown that 14-3-3 and DP3 could 
still bind whether E2F5 was present in the complex or not (Figure 4.2E). This was 
an important point to address since it showed that the DP3/14-3-3 interaction is not 
dependent on the presence of other factors in the complex.
The 5S mutant now provided a powerful tool in analysing the role of the 14-3- 
3/E2F association, via the DP3 sub-unit. The DP3AB mutant had limitations since, 
due to the removal of the basic region, it was largely cytoplasmic. This was 
undesirable in elucidating the role of 14-3-3 with a nuclear transcription factor 
complex. Identification of a mutant of DP3 that was unable to bind 14-3-3 and yet 
retained its nuclear localisation therefore allowed the detailed examination of the 
nature of the DP3/E2F/I4-3-3 association.
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9.2: 14-3-3 does not influence the sub-cellular location of DP3
14-3-3 proteins can indirectly influence the activity of target ligands by altering 
their sub-cellular localisation. It was therefore of interest to examine whether the 
binding to 14-3-3 could influence the sub-cellular localisation of DP3. Furthermore, 
did a lack of binding to the DP3 5S mutant influence the cellular location of 14-3-3. 
hnmunostaining studies showed that 14-3-3 predominantly localised to the nucleus 
when co-expressed with wt DP3 [Figure 5.2A(i)]. However, analysis of the DP3 5S 
mutant and 14-3-3 showed a significant amount of cytoplasmic 14-3-3, indicating 
that the inability to complex with DP3 resulted in the re-localisation of 14-3-3 from 
the nucleus to the cytoplasm [Figure 5.2A(ii)]. This suggested that DP3 acts as 
some sort of nuclear anchor for 14-3-3, preventing its export to the cytoplasm.
This posed the interesting question of whether DP3 was influencing the nuclear 
accumulation of 14-3-3 or whether 14-3-3 that was unable to bind DP3 was simply 
exported back into the cytoplasm via some undefined mechanism. To address this 
question leptomycin B was used to block nuclear export and the immunostaining 
study perfonned in Figure 5.2A was repeated. Unsui-prisingly, 14-3-3 accumulated 
almost exclusively in the nucleus in the presence of the wild type DP3 protein 
[Figure 5.2B(ii)]. However, when 14-3-3 was co-expressed with the 5S mutant it 
again localised predominantly to the nucleus [Figure 5.2B(iii)].
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This result indicates that 14-3-3 is not dependent on the ability to bind DP3 to enter 
the nucleus and that it can actively shuttle between the nucleus and the cytoplasm. 
Given that recent work by Brimet et al., (2002) has now shown that 14-3-3 proteins 
do not contain a nuclear export signal this poses the interesting question of how 
exactly 14-3-3 that is unable to bind to DP3 can enter and exit the nucleus. 
Although the work in chapter 3 has shown that the DP3 5S mutant and 14-3-3 are 
unable to fonn a complex, this does not prove that the interaction is direct. Figure 
5.2B suggests that there may be another protein within the complex that is still able 
to bind to 14-3-3 and which is able to localises it between the nucleus and the 
cytoplasm. This would explain how 14-3-3 that is unable to bind to DP3 is able to 
shuttle between the nucleus and the cytoplasm.
As previously stated in the conclusions in chapter 5 it also camrot be ruled out that 
14-3-3 that is unable to bind to DP3 is then targeted to other endogenous partners 
that localise it predominantly to the cytoplasm. However, if  this was the case it 
could be expected that the same pattern of distribution of 14-3-3 in the presence of 
the DP3 5S mutant would be obseiwed when 14-3-3 is expressed alone. However it 
may be that 14-3-3 that is co-expressed with the DP3 5S mutant behaves in a 
different manner from 14-3-3 that is expressed alone.
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If 14-3-3 is not dependent on DP3 to enter the nucleus then this would allow the 
interaction to be more dynamic, with 14-3-3 responding to the signals to bind DP3 
at any point. Despite this, it may be that the interaction is of a more rigid nature 
since loss of 14-3-3 regulation results in a block in cell cycle progression and an 
apoptotic response.
9.3: 14-3-3 can positively influence E2F"dependent 
cell cycle progression
Both E2F and 14-3-3 proteins play an integi*al role in the control o f the mammalian 
cell cycle. E2F co-ordinates gene expression with S-phase induction whilst 14-3-3 
proteins play an essential role in controlling the activity of proteins involved in cell 
cycle progression. Given this, it was of interest to examine if 14-3-3 had an effect 
on E2F dependent cell cycle progression. The in vitro effect of 14-3-3 on the 
transcriptional activity of E2F via either DP3 wild type or the 5S mutant was 
examined (Figure 6.2A).
Both E2F5/DP3 wild type and E2F5/DP3 5S mutant showed similar levels of 
transcriptional activity on the cyclinE promoter. However, when 14-3-3 was titrated 
in along with the heterodimers the results differed remarkably. Whereas the levels 
of transcriptional activity of the wild type heterodimer increased as more 14-3-3 
was titrated into the system, the transcriptional activity of the mutant heterodimer 
rose slightly but did not increase in the same manner as E2F5/DP3 wild type. This
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result suggested that 14-3-3 can increase the transcriptional activity of E2F5, via 
the DP3 sub-unit. Presumably the lack of binding to the E2F5/DP3 5S complex 
prevents 14-3-3 from enhancing the transcriptional activation of the heterodimer. 
Indeed, work by Waterman et al. (1998) showed that dephosphorylation of p53 at 
serine-376 creates a 14-3-3 binding site at serine-378. This leads to an enhancement 
of p53 DNA binding activity and more effective transcriptional activity.
Given this result, it was of interest to examine what effect this would have in vivo. 
To address this question FACS and Brdu analysis were carried out. The FACS 
analysis (Figure 6.2B) revealed that the E2F5/DP3 wild type heterodimer could 
induce cell cycle progression marginally more than the E2F5/DP3 5S mutant 
construct. However, when 14-3-3 was co-transfected, the amount of cell cycle 
progression observed in the E2F5/DP3 wild type increased significantly whereas 
the E2F5/DP3 5S mutant heterodimer showed only a marginal increase.
Similarly, Brdu analysis, which examines S-phase induction, showed significant 
differences between the wild type and mutant heterodimers (Figure 6.2C). Neither 
the wild type nor mutant heterodimers showed a significant increase in S-phase 
entry over mock when expressed alone. When 14-3-3 was co-expressed, the amount 
of cells in S-phase increased two-fold with the E2F5/DP3 wild type construct 
however no effect was observed with the E2F5/DP3 5S heterodimer. Taken 
together these in vivo results suggest that 14-3-3 tightly controls E2F-mediated S- 
phase entry.
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These observations are slightly surprising given the inhibitory role traditionally 
played by the 14-3-3 proteins in the control of the cell cycle. 14-3-3s are seen to 
block S-phase entry by negatively regulating cdk2 and cdc2 (Laronga et al., 2000) 
and to prevent mitotic onset by sequestering cdc25C in the cytoplasm (Peng et al., 
1997). The sequestration of HDAC4 and HD AC 5 by 14-3-3 proteins in the 
cytoplasm also prevents the gene silencing associated with these proteins 
(Grozinger and Schi'eiber, 2000).
The enliancement of cell cycle progression by 14-3-3, tlmough E2F, is therefore 
unique within the roles that 14-3-3 plays in regulating ligands involved in the cell 
cycle. However, 14-3-3 can entrance the DNA binding activity of p53 (Waterman et 
al., 1998), which may lead to an enlrancement of transcription. Given that 14-3-3 
may act in the same way to enhance the ability of the E2F5/DP3 heterodimer to 
bind the DNA, this could lead to an enhancement of transcriptional activity and 
more efficient cell cycle progression, as was observed in Figures 6.2A-C.
9.4: 14-3-3 negatively regulates E2F5/DP3-mediated apoptosis
14-3-3 proteins are laiown to regulate an array of proteins involved in the apoptotic 
response including Bad (Xing et al., 2000), FKHRLl (Brunet et al., 1999) and 
ASKl (Zhang et a l, 1999). Recent work by Louglrran and La Thangue, (2000) 
showed that E2F4 and E2F5 could induce an apoptotic response in SA0S2 cells.
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This response was dependent on the presence of the transcriptional activation 
domain of the proteins. Given this, it was of interest to investigate whether 14-3-3 
had an effect on the ability of the E2F5/DP3 heterodimer to induce apoptosis.
Subsequent TUNEL analysis revealed similar results to the work by Loughran and 
La Thangue, (2000). Both the wild type and mutant heterodimers could induce 
apoptosis to a similar degree, and this was approximately twenty times higher than 
the mock sample (Figure 7.2A). Upon the co-expression of 14-3-3, the amount of 
apoptosis induced by E2F5/DP3 wild type was reduced significantly. This result is 
in accordance with published data, which support the fact that 14-3-3 proteins have 
a role in suppressing the apoptotic response. Interestingly, the amount of apoptosis 
induced by the DP3 5S mutant and E2F5, when co-expressed with 14-3-3, rose 
slightly. This could be attributed to the 14-3-3 that is unable to bind the DP3 5S 
mutant acting in a similar mamier as when 14-3-3 is expressed alone since this 
itself caused around a tlii'ee to four-fold increase in apoptosis over the mock 
sample. The extra apoptosis observed when 14-3-3 is co-expressed with E2F5 and 
the DP3 5S mutant could also be due to some other role that 14-3-3 canies out 
when unable to bind to the 5S mutant. This may involve the inactivation of an anti- 
apoptotic protein. This remains to be elucidated.
Interestingly, the suppression of E2F5/DP3 mediated apoptosis does not require the 
re-localisation of the complex to the cytoplasm, as is obseiwed in many 14-3-3 
associated apoptotic substrates. 14-3-3 must regulate E2F5/DP3-mediated apoptosis
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in a different manner, possibly by influencing the choice of promoter occupied by 
the heterodimer. Perhaps when bound to 14-3-3 the E2F5/DP3 wild type complex is 
specifically targeted to either an anti-apoptotic gene or the E2F5/DP3/14-3-3 
association could form an inliibitory complex on pro-apoptotic genes. However, 
one possibility was that 14-3-3 was influencing the apoptotic response tlirough the 
regulation of the transactivation domain in E2F5. To test this, the TUNEL analysis 
was repeated with a transcriptionally dead E2F5 construct (Figure 7.2B). As 
expected, and in accordance with the work carried out by Loughran and La 
Thangue, (2000), the removal of the transactivation domain resulted in a significant 
decrease in the amount of apoptosis induced by E2F5. Despite this, the pattern of 
14-3-3 repression of apoptosis remained the same with, yet again, an increase in 
apoptosis when 14-3-3 was co-expressed with the E2F5/DP3 5S heterodimer. This 
result suggested that 14-3-3 was able to regulate E2F5/DP3-mediated apoptosis in a 
manner that was independent of the presence of the trans activation domain.
During S-phase, the cyclinA/cdk2 complex regulates the activity of E2F1/DP1. 
Phosphorylation of DPI and E2F1 results in the reduced binding affinity of the 
heterodimer and the subsequent degradation of both DPI and E2F1 (Ki'ek et ah, 
1994, Xu et al., 1994; Guida and Zhu, 1999; Marti et al., 1999). This allows the 
regulation of the levels of E2F, something that is essential in preventing mis- 
regulation of E2F activity and apoptosis. Given this, it was o f interest to examine if 
the regulation of E2F5/DP3-dependent apoptosis by 14-3-3 was through regulation 
of the stability of the heterodimer.
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Subsequent cycloheximide treatment (Figure 7.2C) showed that the stability of the 
E2F5/DP3 wild type complex was reduced upon the co-expression with 14-3-3. 
The stability of the mutant heterodimer was not affected either in the presence or 
the absence of 14-3-3 and it can therefore be concluded that 14-3-3 regulates the 
protein levels of the E2F5/DP3 complex. Interestingly, the stability of 14-3-3 was 
affected when in association with E2F5/DP3 wild type. This suggests that 14-3-3 
itself is regulated in a similar manner and that it may act as a linlcer molecule 
between E2F5/DP3 and the ubiquination process. In many cases 14-3-3 plays such 
a role, bringing together and linking up various protein-protein interactions.
hitriguingly, the upper form of DP3 had an extended persistence in the cell 
compared to the lower form. This suggests a further level of control that 14-3-3 can 
exert on E2F, based on the protein form of DP3 partner. Although it is unknown 
what both forms of DP3 represent it may be that the lower fonn has been tryptic ally 
digested and this would therefore explain why the lower form is less stable than the 
upper form. Mass spectroscopy should be able to determine exactly what both 
fonns of DP3 are.
9.5: The DP3/14-3-3 interaction is DNA damage responsive
Given the role played by both E2F and 14-3-3 in the DNA damage response it was 
of interest to analyse if the regulation that 14-3-3 exerted over DP3/E2F was 
regulated by DNA damage, hideed. Figure 8.2A showed that the interaction
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between DP3 and 14-3-3 was abrogated following treatment with the DNA 
damaging agent, etoposide. This result suggested that following the damage 
response the phenotypes obseiwed with the DP3 5S mutant would occur. This 
would therefore lead to a negative regulation on the cell cycle and an enliancement 
of the apoptotic response.
Despite this, much more work is required to prove this and Figure 8.2A only 
provides an initial, but interesting result, suggesting that the DP3/14-3-3 interaction 
can be regulated by the response to DNA damage and may be important in a 
checkpoint control mechanism. It may be that the level o f binding is regulated 
depending on the time after the initiation of the DNA damage. Perhaps the 
interaction is completely abrogated after only a few hours and that, after this period, 
DP3 and 14-3-3 re-form a complex. This will be one of the many interesting 
experiments to carry out in the future.
9.6: Overall conclusions and future work
This study has now defined a unique level of control of E2F activity, mediated 
tlu'ough the DP3 component, by the 14-3-3 family o f proteins. The work presented 
here has shown that the abolition of the DP3/14-3-3 interaction results in an 
inliibition of cell cycle progiession and an increase in apoptosis. Based on the 
results presented here I propose a ‘dual role’ model whereby the regulation of E2F 
activity by 14-3-3 proteins is dependent on the binding to the DP3 component and
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that this interaction mediates the stability of the E2F5/DP3 heterodimer (Figure 
9.1).
If a kinase induces the phosphorylation of DP3 on serine residues within the 14-3-3 
binding site in DP3 this could lead to the association of 14-3-3 with DP3. 14-3-3 
may be able to entrance the binding of the heterodimer to the DNA in a manner 
perhaps analogous to that of p53. This could perhaps lead to a more
transcriptionally active E2F5/DP3 complex, which can then induce cell cycle 
progression. Given that Figure 6.2A shows that 14-3-3 can enlrance the
transcriptional activation of E2F5/DP3, and that this effect is titratable, this is an 
entirely plausible model.
I also propose that 14-3-3 can regulate the stability of the heterodimer by linking it 
to the protein degradation process. An inability to bind 14-3-3 leads to the 
accumulation of the E2F5/DP3 heterodimer on the DNA. Since the cell is unable to 
regulate the stability of the complex it initiates an apoptotic response. 14-3-3 can 
prevent this by regulating the levels of E2F5/DP3 and preventing the accumulation 
of the complex, hi this way 14-3-3 acts to ‘cap’ the levels of E2F5/DP3 by allowing 
the continual turnover of the E2F5/DP3/14-3-3 complex.
This model poses some interesting questions. Whether the association between 14- 
3-3 and DP3 occurs in the cytoplasm or in the nucleus is unlmown. Figure 5.2B
suggests that 14-3-3 can actively shuttle between the nucleus and the cytoplasm.
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suggesting that the association may take place when the heterodimer is in complex 
with the DNA, This is unlikely since this would lead to the phenotypes observed 
with the mutant complex. It is likely that the association takes place in the 
cytoplasm and the bi-partite NLS in DP3 causes the nuclear accumulation of both 
E2F5 and 14-3-3. As shown in Figure 7.2A, there is an increase in the levels of 
apoptosis when 14-3-3 is co-expressed with the E2F5/DP3 5S mutant heterodimer. 
Presumably this is caused by the 14-3-3 that is unable to bind to the E2F5/DP3 5S 
heterodimer. Perhaps this unbound 14-3-3 influences the sub-cellular localisation of 
an anti-apoptotic protein, leading to an increase in the apoptotic response.
The proposed model of the regulation of E2F by 14-3-3 raises a variety o f questions 
that must be addressed in future work. Firstly, although the interaction is possibly 
mediated by the phosphorylation of the serine residues within the bi-partite NLS, 
this does not rule out that the mutations made merely disrupts the tertiary structure 
of DP3 sufficiently to abrogated 14-3-3 binding either within the NLS or at another 
site within DP3. 14-3-3 proteins have recently been shown to bind to non- 
phosphorylated motifs in ligands such as 5-phosphatase, exoenzyme S, A20 and the 
platelet glycoprotein IB-IX-V complex (Masters et ah, 1999; Vincenz and Dixit. 
1996; Du et al., 1996; Campbell et al., 1997). It may therefore be the case that 14- 
3-3 can bind to non-phosphorylated motif(s) within DP3 since none of the serines 
that were mutated fit the consensus sequences for 14-3-3 binding ligands.
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It will therefore be of interest to analyse if the binding between 14-3-3 and DP3 can 
be maintained in the presence of phosphatases. If so, and the binding can be shown 
to be phosphoserine-dependent, it will be of interest to investigate what kinases 
may be involved in mediating the binding. Given that all five serine residues were 
mutated, the role played by each one in the binding to 14-3-3 must be elucidated. 
Figure 3.2A shows that the 2S, 3S and 4S mutants have similar levels of reduced 
binding affinity for 14-3-3 compared to the wild type, whilst the 5S mutant is 
completely unable to bind 14-3-3. This suggests that serine-42 may be involved in 
binding and either, or both, of serines-58 or -61 [Figure 3.1(i)].
If the association between DP3 and 14-3-3 is mediated by phosphorylation this 
poses the question of the mechanism that switches the interaction off. Presumably 
the binding is dynamic in nature and 14-3-3 can be bound, or released, from the 
heterodimer depending on intra-cellular and extra-cellular signals. The association 
between p53 and 14-3-3 occurs after DNA damage following the de­
phosphorylation of serine-376 (Waterman et al., 1998). This creates a 14-3-3 
binding site at serine-378. It may be that de-phosphorylation of the serine residues 
is also a critical step in the association between 14-3-3 and DP3. Presumably, de­
phosphorylation would lead to the phenotypes observed with the 5S mutant 
heterodimer.
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In some circumstances this may be desirable for the cell. For instance, after DNA 
damage, a loss of binding would result in a reduction in DNA binding, and an 
accumulation of the heterodimer. This would lead to an inliibition of cell cycle 
progression and a potent apoptotic response. This would allow the cell to positively 
regulate the apoptotic response following DNA damage. Given that 14-3-3a is 
involved in the DNA damage response it is plausible that other isofomis such as 
14-3-38 may be as well. Figure 8.2A would certainly support this idea.
Given this, it would also be of interest to examine the role played by the various 
isoforms of 14-3-3 in the regulation of the E2F/DP3 association. It is possible that 
other isoforms of 14-3-3 can bind DP3, and perhaps regulate the activity of the 
heterodimer in other ways. Previous work in the laboratory suggested that the role 
played by 14-3-3 in the regulation of E2F5/DP3 differed when 14-3-3 associated 
with E2F1/DP3 (Cruickshanlc, 2000). Since the ‘activating’ and ‘repressing’ E2Fs 
have been shown to have functionally distinct characteristics, it may also be that the 
influence that 14-3-3 exerts on E2F is dependent on the member of the family that 
is in complex with DP3.
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Figure 9.1: Model for the Regulation of E2F/DP3 by 14-3-3
If DP3 phosphorylation within the bi-partite NLS leads to the binding of 14-3-3 
DP3 would be able to drive E2F5 and 14-3-3 into the nucleus. 14-3-3 may then be 
able to enliance the binding of the heterodimer to the DNA as well as link the 
E2F5/DP3/14-3-3 complex to the degradation machinery. This could lead to a more 
transcriptionally active E2F5/DP3 heterodimer due to the enhanced DNA binding, 
as well as the ‘capping’ of the levels of the complex. This tight regulation of 
protein levels may therefore be able to prevent the accumulation of E2F5/DP3/14- 
3-3 on the DNA, which could block the induction of an apoptotic response.
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